A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.
A CELL LINE derived from human T-CELL LEUKEMIA and used to determine the mechanism of differential susceptibility to anti-cancer drugs and radiation.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.
Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
A classification of T-lymphocytes, especially into helper/inducer, suppressor/effector, and cytotoxic subsets, based on structurally or functionally different populations of cells.
Species of GAMMARETROVIRUS, containing many well-defined strains, producing leukemia in mice. Disease is commonly induced by injecting filtrates of propagable tumors into newborn mice.
Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (ANTIGENS, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES.
The altered state of immunologic responsiveness resulting from initial contact with antigen, which enables the individual to produce antibodies more rapidly and in greater quantity in response to secondary antigenic stimulus.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) arising during the propagation of S37 mouse sarcoma, and causing lymphoid leukemia in mice. It also infects rats and newborn hamsters. It is apparently transmitted to embryos in utero and to newborns through mother's milk.
Inbred BALB/c mice are a strain of laboratory mice that have been selectively bred to be genetically identical to each other, making them useful for scientific research and experiments due to their consistent genetic background and predictable responses to various stimuli or treatments.
CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow.
A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
Leukemia L1210 is a designation for a specific murine (mouse) leukemia cell line that was originally isolated from a female mouse with an induced acute myeloid leukemia, which is widely used as a model in cancer research, particularly for in vivo studies of drug efficacy and resistance.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Antigenic determinants recognized and bound by the T-cell receptor. Epitopes recognized by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen.
The type species of DELTARETROVIRUS that causes a form of bovine lymphosarcoma (ENZOOTIC BOVINE LEUKOSIS) or persistent lymphocytosis.
A species of GAMMARETROVIRUS causing leukemia, lymphosarcoma, immune deficiency, or other degenerative diseases in cats. Several cellular oncogenes confer on FeLV the ability to induce sarcomas (see also SARCOMA VIRUSES, FELINE).
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognize antigens only when presented in association with major histocompatibility (MHC) molecules.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
An encapsulated lymphatic organ through which venous blood filters.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
A single, unpaired primary lymphoid organ situated in the MEDIASTINUM, extending superiorly into the neck to the lower edge of the THYROID GLAND and inferiorly to the fourth costal cartilage. It is necessary for normal development of immunologic function early in life. By puberty, it begins to involute and much of the tissue is replaced by fat.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia.
Form of passive immunization where previously sensitized immunologic agents (cells or serum) are transferred to non-immune recipients. When transfer of cells is used as a therapy for the treatment of neoplasms, it is called adoptive immunotherapy (IMMUNOTHERAPY, ADOPTIVE).
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Established cell cultures that have the potential to propagate indefinitely.
Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.
Inbred C57BL mice are a strain of laboratory mice that have been produced by many generations of brother-sister matings, resulting in a high degree of genetic uniformity and homozygosity, making them widely used for biomedical research, including studies on genetics, immunology, cancer, and neuroscience.
Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).
Leukemia produced by exposure to IONIZING RADIATION or NON-IONIZING RADIATION.
Myeloid-lymphoid leukemia protein is a transcription factor that maintains high levels of HOMEOTIC GENE expression during development. The GENE for myeloid-lymphoid leukemia protein is commonly disrupted in LEUKEMIA and combines with over 40 partner genes to form FUSION ONCOGENE PROTEINS.
T-cell receptors composed of CD3-associated gamma and delta polypeptide chains and expressed primarily in CD4-/CD8- T-cells. The receptors appear to be preferentially located in epithelial sites and probably play a role in the recognition of bacterial antigens. The T-cell receptor gamma/delta chains are separate and not related to the gamma and delta chains which are subunits of CD3 (see ANTIGENS, CD3).
Antibodies produced by a single clone of cells.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.
Costimulatory T-LYMPHOCYTE receptors that have specificity for CD80 ANTIGEN and CD86 ANTIGEN. Activation of this receptor results in increased T-cell proliferation, cytokine production and promotion of T-cell survival.
The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
The number of LYMPHOCYTES per unit volume of BLOOD.
55-kDa antigens found on HELPER-INDUCER T-LYMPHOCYTES and on a variety of other immune cell types. CD4 antigens are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MAJOR HISTOCOMPATIBILITY COMPLEX class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. CD4 antigens also serve as INTERLEUKIN-15 receptors and bind to the HIV receptors, binding directly to the HIV ENVELOPE PROTEIN GP120.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) producing leukemia of the reticulum-cell type with massive infiltration of liver, spleen, and bone marrow. It infects DBA/2 and Swiss mice.
An acute leukemia exhibiting cell features characteristic of both the myeloid and lymphoid lineages and probably arising from MULTIPOTENT STEM CELLS.
Antigens expressed on the cell membrane of T-lymphocytes during differentiation, activation, and normal and neoplastic transformation. Their phenotypic characterization is important in differential diagnosis and studies of thymic ontogeny and T-cell function.
Disease having a short and relatively severe course.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
High-molecular weight glycoproteins uniquely expressed on the surface of LEUKOCYTES and their hemopoietic progenitors. They contain a cytoplasmic protein tyrosine phosphatase activity which plays a role in intracellular signaling from the CELL SURFACE RECEPTORS. The CD45 antigens occur as multiple isoforms that result from alternative mRNA splicing and differential usage of three exons.
A subclass of winged helix DNA-binding proteins that share homology with their founding member fork head protein, Drosophila.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Receptors present on activated T-LYMPHOCYTES and B-LYMPHOCYTES that are specific for INTERLEUKIN-2 and play an important role in LYMPHOCYTE ACTIVATION. They are heterotrimeric proteins consisting of the INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT, the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT, and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8)
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Glycoproteins found on the membrane or surface of cells.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
Subpopulation of CD4+ lymphocytes that cooperate with other lymphocytes (either T or B) to initiate a variety of immune functions. For example, helper-inducer T-cells cooperate with B-cells to produce antibodies to thymus-dependent antigens and with other subpopulations of T-cells to initiate a variety of cell-mediated immune functions.
A low affinity interleukin-2 receptor subunit that combines with the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN to form a high affinity receptor for INTERLEUKIN-2.
An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common.
Subset of helper-inducer T-lymphocytes which synthesize and secrete interleukin-2, gamma-interferon, and interleukin-12. Due to their ability to kill antigen-presenting cells and their lymphokine-mediated effector activity, Th1 cells are associated with vigorous delayed-type hypersensitivity reactions.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.
Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) isolated from spontaneous leukemia in AKR strain mice.
Therapeutic act or process that initiates a response to a complete or partial remission level.
A soluble factor produced by activated T-LYMPHOCYTES that induces the expression of MHC CLASS II GENES and FC RECEPTORS on B-LYMPHOCYTES and causes their proliferation and differentiation. It also acts on T-lymphocytes, MAST CELLS, and several other hematopoietic lineage cells.
The initial phase of chronic myeloid leukemia consisting of an relatively indolent period lasting from 4 to 7 years. Patients range from asymptomatic to those exhibiting ANEMIA; SPLENOMEGALY; and increased cell turnover. There are 5% or fewer blast cells in the blood and bone marrow in this phase.
A technique of culturing mixed cell types in vitro to allow their synergistic or antagonistic interactions, such as on CELL DIFFERENTIATION or APOPTOSIS. Coculture can be of different types of cells, tissues, or organs from normal or disease states.
An ERYTHROLEUKEMIA cell line derived from a CHRONIC MYELOID LEUKEMIA patient in BLAST CRISIS.
Substances that are recognized by the immune system and induce an immune reaction.
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
Cell separation is the process of isolating and distinguishing specific cell types or individual cells from a heterogeneous mixture, often through the use of physical or biological techniques.
A strain of PRIMATE T-LYMPHOTROPIC VIRUS 1 isolated from mature T4 cells in patients with T-lymphoproliferation malignancies. It causes adult T-cell leukemia (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), T-cell lymphoma (LYMPHOMA, T-CELL), and is involved in mycosis fungoides, SEZARY SYNDROME and tropical spastic paraparesis (PARAPARESIS, TROPICAL SPASTIC).
Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
An albumin obtained from the white of eggs. It is a member of the serpin superfamily.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
A cell line derived from cultured tumor cells.
Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Subset of helper-inducer T-lymphocytes which synthesize and secrete the interleukins IL-4, IL-5, IL-6, and IL-10. These cytokines influence B-cell development and antibody production as well as augmenting humoral responses.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
Sites on an antigen that interact with specific antibodies.

Gene expression profiles in HTLV-I-immortalized T cells: deregulated expression of genes involved in apoptosis regulation. (1/629)

Human T-cell leukemia virus type I (HTLV-I) is the etiologic agent of adult T-cell leukemia, an acute and often fatal T-cell malignancy. A key step in HTLV-I-induced leukemigenesis is induction of abnormal T-cell growth and survival. Unlike antigen-stimulated T cells, which cease proliferation after a finite number of cell division, HTLV-I-infected T cells proliferate indefinitely (immortalized), thus facilitating occurrence of secondary genetic changes leading to malignant transformation. To explore the molecular basis of HTLV-I-induced abnormal T-cell survival, we compared the gene expression profiles of normal and HTLV-I-immortalized T cells using 'gene array'. These studies revealed a strikingly altered expression pattern of a large number of genes along with HTLV-I-mediated T-cell immortalization. Interestingly, many of these deregulated genes are involved in the control of programmed cell death or apoptosis. These findings indicate that disruption of the cellular apoptosis-regulatory network may play a role in the HTLV-I-mediated oncogenesis.  (+info)

Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. (2/629)

A limited number of patients with adult T cell leukemia/lymphoma (ATL) who received autologous stem cell transplantation (ASCT) have been reported. We report here a case of fatal systemic Candida krusei infection in a female patient with ATL undergoing ASCT. All of the eight patients (including seven patients in the literature) with ATL who received ASCT developed relapse of ATL or death due to ASCT complication, irrespective of subtype or remission state of ATL, source or selection of SCT or conditioning regimen. At present, ASCT appears to provide little benefit for ATL in contrast to that for other types of aggressive non-Hodgkin's lymphoma.  (+info)

Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line. (3/629)

The effects of 4-demethoxydaunorubicin (idarubicin, IDA) and MX2, a new morpholino-anthracycline, on up-regulation of the MDR1 gene in the low-level multidrug resistant (MDR) cell line CEM/A7R were compared at similar concentrations (IC10, IC50 and IC90) over a short time exposure (4 and 24 h). The chemosensitivity of each drug was determined by a 3-day cell growth inhibition assay. Compared with epirubicin (EPI), IDA and MX2 were 17- and eightfold more effective in the CEM/A7R line respectively. No cross-resistance to 5-FU was seen in the CEM/A7R line. Verapamil (5 microM) and PSC 833 (1 microM), which dramatically reversed resistance to EPI in the CEM/A7R line, had no sensitizing effect on the resistance of this line to MX2, but slightly decreased resistance to IDA. The sensitivity to 5-FU was unchanged by these modulators. The induction of MDR1 mRNA expression by IDA, MX2 and 5-FU was analysed by Northern blotting and semiquantitatively assessed by scanning Northern blots on a phosphorimager. The relative level of MDR1 expression was expressed as a ratio of MDR1 mRNA to the internal RNA control glyceraldehyde-3-phosphate dehydrogenase (GAPDH). IDA, MX2 and 5-FU differentially up-regulated MDR1 mRNA in the CEM/A7R line in a dose-dependent manner. Both IDA and MX2 induced MDR1 expression within 4 h. 5-FU up-regulated MDR1 expression only when drug exposure was prolonged to 24 h. Based on MRK 16 binding, flow cytometric analysis of P-glycoprotein (Pgp) expression paralleled the increase in MDR1 mRNA levels. For the three anthracyclines, the increase in MDR1 expression was stable in cells grown in the absence of drug for more than 3 weeks after drug treatment. The induction of MDR1 expression by 5-FU was transient, associated with a rapid decrease in the increased Pgp levels which returned to baseline 72 h after the removal of 5-FU. This study demonstrates that MDR1 expression can be induced by analogues of anthracyclines not pumped by Pgp, and that this induction appears to be stable despite a 3-week drug-free period.  (+info)

Human T-cell leukemia retrovirus-Tax protein is a repressor of nuclear receptor signaling. (4/629)

The Tax oncoprotein promotes cellular transformation and is associated with the pathogenesis of adult T-cell leukemia. Tax expression activates transcription via the cAMP enhancer binding protein/activating transcription factor (CREB/ATF) and NF-kappaB pathways. In contrast to its positive action, here we demonstrate that Tax is a potent repressor of steroid and retinoid receptor transcription. The Tax protein becomes localized in the promyelocytic (PML) oncogenic domain, and unexpectedly, expression of the PML protein reverses Tax-induced repression. These results suggest that PML and Tax may act in opposing manners to influence nuclear receptor transcription and human T-cell leukemia retrovirus pathogenesis.  (+info)

Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes. (5/629)

The TCL1 oncogene on human chromosome 14q32.1 is involved in the development of T cell leukemia in humans. Its expression in these leukemias is activated by chromosomal translocations and inversions at 14q32.1. Here we report the isolation and characterization of a new member of the TCL1 gene family, TCL1b, located approximately 16 kb centromeric of TCL1. The 1.2-kb TCL1b cDNA encodes a 14-kDa protein of 128 aa and shows 60% similarity to Tcl1. Expression profiles of TCL1 and TCL1b genes are very similar: both genes are expressed at very low levels in normal bone marrow and peripheral lymphocytes but are activated in T cell leukemia by rearrangements of the 14q32.1 region. Thus, translocations and inversions at 14q32. 1 in T cell malignancies involve two oncogenes.  (+info)

Glucocorticoid-induced cell death requires autoinduction of glucocorticoid receptor expression in human leukemic T cells. (6/629)

In contrast to the negative autoregulation of glucocorticoid receptor (GR) expression seen in most cells and tissues, GR expression is positively autoregulated in human leukemic T cells and in other cells sensitive to glucocorticoid-induced cell death. To determine whether positive autoregulation is a necessary component of glucocorticoid-induced cell death, a wild-type GR gene under the control of a tetracycline-regulated promoter was stably transfected into glucocorticoid-resistant cells lacking endogenous functional receptor. Transfectants grown in the presence of tetracycline contained about 15,000 receptors/cell, a value approximately equal to basal level GR expression in glucocorticoid-sensitive 6TG1.1 cells before steroid treatment. Under these conditions, dexamethasone had a minimal effect on cell growth, elicited little internucleosomal DNA fragmentation, and induced no cell cycle perturbation. In the absence of tetracycline, GR mRNA and protein expression increased 2-3-fold, and cells expressed 48,000 receptors, a level nearly equivalent to that present in 6TG1.1 cells after 18 h of autoinduction. Under these conditions, dexamethasone markedly inhibited cell growth, caused G1 arrest, and induced significant internucleosomal DNA fragmentation. These studies therefore suggest that basal level GR expression is inadequate to mediate glucocorticoid-induced apoptosis in glucocorticoid-sensitive T cells and that positive autoregulation is a necessary component of this process.  (+info)

Inhibition of caspases inhibits the release of apoptotic bodies: Bcl-2 inhibits the initiation of formation of apoptotic bodies in chemotherapeutic agent-induced apoptosis. (7/629)

During apoptosis, the cell actively dismantles itself and reduces cell size by the formation and pinching off of portions of cytoplasm and nucleus as "apoptotic bodies." We have combined our previously established quantitative assay relating the amount of release of [3H]-membrane lipid to the degree of apoptosis with electron microscopy (EM) at a series of timepoints to study apoptosis of lymphoid cells exposed to vincristine or etoposide. We find that the [3H]-membrane lipid release assay correlates well with EM studies showing the formation and release of apoptotic bodies and cell death, and both processes are regulated in parallel by inducers or inhibitors of apoptosis. Overexpression of Bcl-2 or inhibition of caspases by DEVD inhibited equally well the activation of caspases as indicated by PARP cleavage. They also inhibited [3H]-membrane lipid release and release of apoptotic bodies. EM showed that cells overexpressing Bcl-2 displayed near-normal morphology and viability in response to vincristine or etoposide. In contrast, DEVD did not prevent cell death. Although DEVD inhibited the chromatin condensation, PARP cleavage, release of apoptotic bodies, and release of labeled lipid, DEVD-treated cells showed accumulation of heterogeneous vesicles trapped in the condensed cytoplasm. These results suggest that inhibition of caspases arrested the maturation and release of apoptotic bodies. Our results also imply that Bcl-2 regulates processes in addition to caspase activation.  (+info)

Concurrent infection with Legionella pneumophila and Pneumocystis carinii in a patient with adult T cell leukemia. (8/629)

A 48-year-old woman was admitted to our hospital with high fever, chills, cough, and exertional dyspnea. On admission, the chest roentgenogram and computed tomography scan showed bilateral alveolar infiltration in the middle and lower lung fields. Microscopic examination of the bronchial lavage fluid showed flower cells typical for adult T-cell leukemia (ATL) and cysts of Pneumocystis carinii, and Legionella pneumophila serogroup 1 grew on buffered charcoal yeast extract (BCYE)-alpha agar. The patient was successfully treated with antibiotics including trimethoprim/sulfamethoxazole, erythromycin, and sparfloxacin. Remission of ATL was achieved after three courses of antileukemic chemotherapy. Mixed infection of opportunistic pathogens should be considered in patients with ATL.  (+info)

Leukemia, T-cell is a type of cancer that affects the T-cells or T-lymphocytes, which are a type of white blood cells responsible for cell-mediated immunity. It is characterized by an excessive and uncontrolled production of abnormal T-cells in the bone marrow, leading to the displacement of healthy cells and impairing the body's ability to fight infections and regulate immune responses.

T-cell leukemia can be acute or chronic, depending on the rate at which the disease progresses. Acute T-cell leukemia progresses rapidly, while chronic T-cell leukemia has a slower course of progression. Symptoms may include fatigue, fever, frequent infections, weight loss, easy bruising or bleeding, and swollen lymph nodes. Treatment typically involves chemotherapy, radiation therapy, stem cell transplantation, or targeted therapy, depending on the type and stage of the disease.

Jurkat cells are a type of human immortalized T lymphocyte (a type of white blood cell) cell line that is commonly used in scientific research. They were originally isolated from the peripheral blood of a patient with acute T-cell leukemia. Jurkat cells are widely used as a model system to study T-cell activation, signal transduction, and apoptosis (programmed cell death). They are also used in the study of HIV infection and replication, as they can be infected with the virus and used to investigate viral replication and host cell responses.

Leukemia is a type of cancer that originates from the bone marrow - the soft, inner part of certain bones where new blood cells are made. It is characterized by an abnormal production of white blood cells, known as leukocytes or blasts. These abnormal cells accumulate in the bone marrow and interfere with the production of normal blood cells, leading to a decrease in red blood cells (anemia), platelets (thrombocytopenia), and healthy white blood cells (leukopenia).

There are several types of leukemia, classified based on the specific type of white blood cell affected and the speed at which the disease progresses:

1. Acute Leukemias - These types of leukemia progress rapidly, with symptoms developing over a few weeks or months. They involve the rapid growth and accumulation of immature, nonfunctional white blood cells (blasts) in the bone marrow and peripheral blood. The two main categories are:
- Acute Lymphoblastic Leukemia (ALL) - Originates from lymphoid progenitor cells, primarily affecting children but can also occur in adults.
- Acute Myeloid Leukemia (AML) - Develops from myeloid progenitor cells and is more common in older adults.

2. Chronic Leukemias - These types of leukemia progress slowly, with symptoms developing over a period of months to years. They involve the production of relatively mature, but still abnormal, white blood cells that can accumulate in large numbers in the bone marrow and peripheral blood. The two main categories are:
- Chronic Lymphocytic Leukemia (CLL) - Affects B-lymphocytes and is more common in older adults.
- Chronic Myeloid Leukemia (CML) - Originates from myeloid progenitor cells, characterized by the presence of a specific genetic abnormality called the Philadelphia chromosome. It can occur at any age but is more common in middle-aged and older adults.

Treatment options for leukemia depend on the type, stage, and individual patient factors. Treatments may include chemotherapy, targeted therapy, immunotherapy, stem cell transplantation, or a combination of these approaches.

Acute myeloid leukemia (AML) is a type of cancer that originates in the bone marrow, the soft inner part of certain bones where new blood cells are made. In AML, the immature cells, called blasts, in the bone marrow fail to mature into normal blood cells. Instead, these blasts accumulate and interfere with the production of normal blood cells, leading to a shortage of red blood cells (anemia), platelets (thrombocytopenia), and normal white blood cells (leukopenia).

AML is called "acute" because it can progress quickly and become severe within days or weeks without treatment. It is a type of myeloid leukemia, which means that it affects the myeloid cells in the bone marrow. Myeloid cells are a type of white blood cell that includes monocytes and granulocytes, which help fight infection and defend the body against foreign invaders.

In AML, the blasts can build up in the bone marrow and spread to other parts of the body, including the blood, lymph nodes, liver, spleen, and brain. This can cause a variety of symptoms, such as fatigue, fever, frequent infections, easy bruising or bleeding, and weight loss.

AML is typically treated with a combination of chemotherapy, radiation therapy, and/or stem cell transplantation. The specific treatment plan will depend on several factors, including the patient's age, overall health, and the type and stage of the leukemia.

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from cells that become certain white blood cells (called lymphocytes) in the bone marrow. The cancer (leukemia) cells start in the bone marrow but then go into the blood.

In CLL, the leukemia cells often build up slowly. Many people don't have any symptoms for at least a few years. But over time, the cells can spread to other parts of the body, including the lymph nodes, liver, and spleen.

The "B-cell" part of the name refers to the fact that the cancer starts in a type of white blood cell called a B lymphocyte or B cell. The "chronic" part means that this leukemia usually progresses more slowly than other types of leukemia.

It's important to note that chronic lymphocytic leukemia is different from chronic myelogenous leukemia (CML). Although both are cancers of the white blood cells, they start in different types of white blood cells and progress differently.

Leukemia, lymphoid is a type of cancer that affects the lymphoid cells, which are a vital part of the body's immune system. It is characterized by the uncontrolled production of abnormal white blood cells (leukocytes or WBCs) in the bone marrow, specifically the lymphocytes. These abnormal lymphocytes accumulate and interfere with the production of normal blood cells, leading to a decrease in red blood cells (anemia), platelets (thrombocytopenia), and healthy white blood cells (leukopenia).

There are two main types of lymphoid leukemia: acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). Acute lymphoblastic leukemia progresses rapidly, while chronic lymphocytic leukemia has a slower onset and progression.

Symptoms of lymphoid leukemia may include fatigue, frequent infections, easy bruising or bleeding, weight loss, swollen lymph nodes, and bone pain. Treatment options depend on the type, stage, and individual patient factors but often involve chemotherapy, radiation therapy, targeted therapy, immunotherapy, or stem cell transplantation.

Experimental leukemia refers to the stage of research or clinical trials where new therapies, treatments, or diagnostic methods are being studied for leukemia. Leukemia is a type of cancer that affects the blood and bone marrow, leading to an overproduction of abnormal white blood cells.

In the experimental stage, researchers investigate various aspects of leukemia, such as its causes, progression, and potential treatments. They may conduct laboratory studies using cell cultures or animal models to understand the disease better and test new therapeutic approaches. Additionally, clinical trials may be conducted to evaluate the safety and efficacy of novel treatments in human patients with leukemia.

Experimental research in leukemia is crucial for advancing our understanding of the disease and developing more effective treatment strategies. It involves a rigorous and systematic process that adheres to ethical guidelines and scientific standards to ensure the validity and reliability of the findings.

Chronic myelogenous leukemia (CML), BCR-ABL positive is a specific subtype of leukemia that originates in the bone marrow and involves the excessive production of mature granulocytes, a type of white blood cell. It is characterized by the presence of the Philadelphia chromosome, which is formed by a genetic translocation between chromosomes 9 and 22, resulting in the formation of the BCR-ABL fusion gene. This gene encodes for an abnormal protein with increased tyrosine kinase activity, leading to uncontrolled cell growth and division. The presence of this genetic abnormality is used to confirm the diagnosis and guide treatment decisions.

T-lymphocyte subsets refer to distinct populations of T-cells, which are a type of white blood cell that plays a central role in cell-mediated immunity. The two main types of T-lymphocytes are CD4+ and CD8+ cells, which are defined by the presence or absence of specific proteins called cluster differentiation (CD) molecules on their surface.

CD4+ T-cells, also known as helper T-cells, play a crucial role in activating other immune cells, such as B-lymphocytes and macrophages, to mount an immune response against pathogens. They also produce cytokines that help regulate the immune response.

CD8+ T-cells, also known as cytotoxic T-cells, directly kill infected cells or tumor cells by releasing toxic substances such as perforins and granzymes.

The balance between these two subsets of T-cells is critical for maintaining immune homeostasis and mounting effective immune responses against pathogens while avoiding excessive inflammation and autoimmunity. Therefore, the measurement of T-lymphocyte subsets is essential in diagnosing and monitoring various immunological disorders, including HIV infection, cancer, and autoimmune diseases.

Medical Definition:

Murine leukemia virus (MLV) is a type of retrovirus that primarily infects and causes various types of malignancies such as leukemias and lymphomas in mice. It is a complex genus of viruses, with many strains showing different pathogenic properties.

MLV contains two identical single-stranded RNA genomes and has the ability to reverse transcribe its RNA into DNA upon infection, integrating this proviral DNA into the host cell's genome. This is facilitated by an enzyme called reverse transcriptase, which MLV carries within its viral particle.

The virus can be horizontally transmitted between mice through close contact with infected saliva, urine, or milk. Vertical transmission from mother to offspring can also occur either in-utero or through the ingestion of infected breast milk.

MLV has been extensively studied as a model system for retroviral pathogenesis and tumorigenesis, contributing significantly to our understanding of oncogenes and their role in cancer development. It's important to note that Murine Leukemia Virus does not infect humans.

1. Receptors: In the context of physiology and medicine, receptors are specialized proteins found on the surface of cells or inside cells that detect and respond to specific molecules, known as ligands. These interactions can trigger a range of responses within the cell, such as starting a signaling pathway or changing the cell's behavior. There are various types of receptors, including ion channels, G protein-coupled receptors, and enzyme-linked receptors.

2. Antigen: An antigen is any substance (usually a protein) that can be recognized by the immune system, specifically by antibodies or T-cells, as foreign and potentially harmful. Antigens can be derived from various sources, such as bacteria, viruses, fungi, parasites, or even non-living substances like pollen, chemicals, or toxins. An antigen typically contains epitopes, which are the specific regions that antibodies or T-cell receptors recognize and bind to.

3. T-Cell: Also known as T lymphocytes, T-cells are a type of white blood cell that plays a crucial role in cell-mediated immunity, a part of the adaptive immune system. They are produced in the bone marrow and mature in the thymus gland. There are several types of T-cells, including CD4+ helper T-cells, CD8+ cytotoxic T-cells, and regulatory T-cells (Tregs). T-cells recognize antigens presented to them by antigen-presenting cells (APCs) via their surface receptors called the T-cell receptor (TCR). Once activated, T-cells can proliferate and differentiate into various effector cells that help eliminate infected or damaged cells.

Precursor Cell Lymphoblastic Leukemia-Lymphoma (previously known as Precursor T-lymphoblastic Leukemia/Lymphoma) is a type of cancer that affects the early stages of T-cell development. It is a subtype of acute lymphoblastic leukemia (ALL), which is characterized by the overproduction of immature white blood cells called lymphoblasts in the bone marrow, blood, and other organs.

In Precursor Cell Lymphoblastic Leukemia-Lymphoma, these abnormal lymphoblasts accumulate primarily in the lymphoid tissues such as the thymus and lymph nodes, leading to the enlargement of these organs. This subtype is more aggressive than other forms of ALL and has a higher risk of spreading to the central nervous system (CNS).

The medical definition of Precursor Cell Lymphoblastic Leukemia-Lymphoma includes:

1. A malignant neoplasm of immature T-cell precursors, also known as lymphoblasts.
2. Characterized by the proliferation and accumulation of these abnormal cells in the bone marrow, blood, and lymphoid tissues such as the thymus and lymph nodes.
3. Often associated with chromosomal abnormalities, genetic mutations, or aberrant gene expression that contribute to its aggressive behavior and poor prognosis.
4. Typically presents with symptoms related to bone marrow failure (anemia, neutropenia, thrombocytopenia), lymphadenopathy (swollen lymph nodes), hepatosplenomegaly (enlarged liver and spleen), and potential CNS involvement.
5. Diagnosed through a combination of clinical evaluation, imaging studies, and laboratory tests, including bone marrow aspiration and biopsy, immunophenotyping, cytogenetic analysis, and molecular genetic testing.
6. Treated with intensive multi-agent chemotherapy regimens, often combined with radiation therapy and/or stem cell transplantation to achieve remission and improve survival outcomes.

Flow cytometry is a medical and research technique used to measure physical and chemical characteristics of cells or particles, one cell at a time, as they flow in a fluid stream through a beam of light. The properties measured include:

* Cell size (light scatter)
* Cell internal complexity (granularity, also light scatter)
* Presence or absence of specific proteins or other molecules on the cell surface or inside the cell (using fluorescent antibodies or other fluorescent probes)

The technique is widely used in cell counting, cell sorting, protein engineering, biomarker discovery and monitoring disease progression, particularly in hematology, immunology, and cancer research.

CD4-positive T-lymphocytes, also known as CD4+ T cells or helper T cells, are a type of white blood cell that plays a crucial role in the immune response. They express the CD4 receptor on their surface and help coordinate the immune system's response to infectious agents such as viruses and bacteria.

CD4+ T cells recognize and bind to specific antigens presented by antigen-presenting cells, such as dendritic cells or macrophages. Once activated, they can differentiate into various subsets of effector cells, including Th1, Th2, Th17, and Treg cells, each with distinct functions in the immune response.

CD4+ T cells are particularly important in the immune response to HIV (human immunodeficiency virus), which targets and destroys these cells, leading to a weakened immune system and increased susceptibility to opportunistic infections. The number of CD4+ T cells is often used as a marker of disease progression in HIV infection, with lower counts indicating more advanced disease.

Acute Monocytic Leukemia (AML-M5) is a subtype of acute myeloid leukemia (AML), which is a type of cancer affecting the blood and bone marrow. In AML-M5, there is an overproduction of abnormal monocytes, a type of white blood cell that normally helps fight infection and is involved in the body's immune response. These abnormal monocytes accumulate in the bone marrow and interfere with the production of normal blood cells, leading to symptoms such as fatigue, frequent infections, and easy bruising or bleeding. The disease progresses rapidly without treatment, making it crucial to begin therapy as soon as possible after diagnosis.

Immunologic memory, also known as adaptive immunity, refers to the ability of the immune system to recognize and mount a more rapid and effective response upon subsequent exposure to a pathogen or antigen that it has encountered before. This is a key feature of the vertebrate immune system and allows for long-term protection against infectious diseases.

Immunologic memory is mediated by specialized cells called memory T cells and B cells, which are produced during the initial response to an infection or immunization. These cells persist in the body after the pathogen has been cleared and can quickly respond to future encounters with the same or similar antigens. This rapid response leads to a more effective and efficient elimination of the pathogen, resulting in fewer symptoms and reduced severity of disease.

Immunologic memory is the basis for vaccines, which work by exposing the immune system to a harmless form of a pathogen or its components, inducing an initial response and generating memory cells that provide long-term protection against future infections.

Transgenic mice are genetically modified rodents that have incorporated foreign DNA (exogenous DNA) into their own genome. This is typically done through the use of recombinant DNA technology, where a specific gene or genetic sequence of interest is isolated and then introduced into the mouse embryo. The resulting transgenic mice can then express the protein encoded by the foreign gene, allowing researchers to study its function in a living organism.

The process of creating transgenic mice usually involves microinjecting the exogenous DNA into the pronucleus of a fertilized egg, which is then implanted into a surrogate mother. The offspring that result from this procedure are screened for the presence of the foreign DNA, and those that carry the desired genetic modification are used to establish a transgenic mouse line.

Transgenic mice have been widely used in biomedical research to model human diseases, study gene function, and test new therapies. They provide a valuable tool for understanding complex biological processes and developing new treatments for a variety of medical conditions.

The Moloney murine leukemia virus (Mo-MLV) is a type of retrovirus, specifically a gammaretrovirus, that is commonly found in mice. It was first discovered and isolated by John Moloney in 1960. Mo-MLV is known to cause various types of cancerous conditions, particularly leukemia, in susceptible mouse strains.

Mo-MLV has a single-stranded RNA genome that is reverse transcribed into double-stranded DNA upon infection of the host cell. This viral DNA then integrates into the host's genome and utilizes the host's cellular machinery to produce new virus particles. The Mo-MLV genome encodes for several viral proteins, including gag (group-specific antigen), pol (polymerase), and env (envelope) proteins, which are essential for the replication cycle of the virus.

Mo-MLV is widely used in laboratory research as a model retrovirus to study various aspects of viral replication, gene therapy, and oncogenesis. It has also been engineered as a vector for gene delivery applications due to its ability to efficiently integrate into the host genome and deliver large DNA sequences. However, it is important to note that Mo-MLV and other retroviruses have the potential to cause insertional mutagenesis, which can lead to unintended genetic alterations and adverse effects in some cases.

BALB/c is an inbred strain of laboratory mouse that is widely used in biomedical research. The strain was developed at the Institute of Cancer Research in London by Henry Baldwin and his colleagues in the 1920s, and it has since become one of the most commonly used inbred strains in the world.

BALB/c mice are characterized by their black coat color, which is determined by a recessive allele at the tyrosinase locus. They are also known for their docile and friendly temperament, making them easy to handle and work with in the laboratory.

One of the key features of BALB/c mice that makes them useful for research is their susceptibility to certain types of tumors and immune responses. For example, they are highly susceptible to developing mammary tumors, which can be induced by chemical carcinogens or viral infection. They also have a strong Th2-biased immune response, which makes them useful models for studying allergic diseases and asthma.

BALB/c mice are also commonly used in studies of genetics, neuroscience, behavior, and infectious diseases. Because they are an inbred strain, they have a uniform genetic background, which makes it easier to control for genetic factors in experiments. Additionally, because they have been bred in the laboratory for many generations, they are highly standardized and reproducible, making them ideal subjects for scientific research.

Regulatory T-lymphocytes (Tregs), also known as suppressor T cells, are a subpopulation of T-cells that play a critical role in maintaining immune tolerance and preventing autoimmune diseases. They function to suppress the activation and proliferation of other immune cells, thereby regulating the immune response and preventing it from attacking the body's own tissues.

Tregs constitutively express the surface markers CD4 and CD25, as well as the transcription factor Foxp3, which is essential for their development and function. They can be further divided into subsets based on their expression of other markers, such as CD127 and CD45RA.

Tregs are critical for maintaining self-tolerance by suppressing the activation of self-reactive T cells that have escaped negative selection in the thymus. They also play a role in regulating immune responses to foreign antigens, such as those encountered during infection or cancer, and can contribute to the immunosuppressive microenvironment found in tumors.

Dysregulation of Tregs has been implicated in various autoimmune diseases, including type 1 diabetes, rheumatoid arthritis, and multiple sclerosis, as well as in cancer and infectious diseases. Therefore, understanding the mechanisms that regulate Treg function is an important area of research with potential therapeutic implications.

Interferon-gamma (IFN-γ) is a soluble cytokine that is primarily produced by the activation of natural killer (NK) cells and T lymphocytes, especially CD4+ Th1 cells and CD8+ cytotoxic T cells. It plays a crucial role in the regulation of the immune response against viral and intracellular bacterial infections, as well as tumor cells. IFN-γ has several functions, including activating macrophages to enhance their microbicidal activity, increasing the presentation of major histocompatibility complex (MHC) class I and II molecules on antigen-presenting cells, stimulating the proliferation and differentiation of T cells and NK cells, and inducing the production of other cytokines and chemokines. Additionally, IFN-γ has direct antiproliferative effects on certain types of tumor cells and can enhance the cytotoxic activity of immune cells against infected or malignant cells.

Hairy cell leukemia (HCL) is a rare, slow-growing type of cancer in which the bone marrow makes too many B cells (a type of white blood cell). These excess B cells are often referred to as "hairy cells" because they look abnormal under the microscope, with fine projections or "hair-like" cytoplasmic protrusions.

In HCL, these abnormal B cells can build up in the bone marrow and spleen, causing both of them to enlarge. The accumulation of hairy cells in the bone marrow can crowd out healthy blood cells, leading to a shortage of red blood cells (anemia), platelets (thrombocytopenia), and normal white blood cells (leukopenia). This can result in fatigue, increased risk of infection, and easy bruising or bleeding.

HCL is typically an indolent disease, meaning that it progresses slowly over time. However, some cases may require treatment to manage symptoms and prevent complications. Treatment options for HCL include chemotherapy, immunotherapy, targeted therapy, and stem cell transplantation. Regular follow-up with a healthcare provider is essential to monitor the disease's progression and adjust treatment plans as needed.

Leukemia, B-cell is a type of cancer that affects the blood and bone marrow, characterized by an overproduction of abnormal B-lymphocytes, a type of white blood cell. These abnormal cells accumulate in the bone marrow and interfere with the production of normal blood cells, leading to anemia, infection, and bleeding.

B-cells are a type of lymphocyte that plays a crucial role in the immune system by producing antibodies to help fight off infections. In B-cell leukemia, the cancerous B-cells do not mature properly and accumulate in the bone marrow, leading to a decrease in the number of healthy white blood cells, red blood cells, and platelets.

There are several types of B-cell leukemia, including acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). ALL is more common in children and young adults, while CLL is more common in older adults. Treatment options for B-cell leukemia depend on the type and stage of the disease and may include chemotherapy, radiation therapy, stem cell transplantation, or targeted therapies.

Interleukin-2 (IL-2) is a type of cytokine, which are signaling molecules that mediate and regulate immunity, inflammation, and hematopoiesis. Specifically, IL-2 is a growth factor for T cells, a type of white blood cell that plays a central role in the immune response. It is primarily produced by CD4+ T cells (also known as T helper cells) and stimulates the proliferation and differentiation of activated T cells, including effector T cells and regulatory T cells. IL-2 also has roles in the activation and function of other immune cells, such as B cells, natural killer cells, and dendritic cells. Dysregulation of IL-2 production or signaling can contribute to various pathological conditions, including autoimmune diseases, chronic infections, and cancer.

CD8-positive T-lymphocytes, also known as CD8+ T cells or cytotoxic T cells, are a type of white blood cell that plays a crucial role in the adaptive immune system. They are named after the CD8 molecule found on their surface, which is a protein involved in cell signaling and recognition.

CD8+ T cells are primarily responsible for identifying and destroying virus-infected cells or cancerous cells. When activated, they release cytotoxic granules that contain enzymes capable of inducing apoptosis (programmed cell death) in the target cells. They also produce cytokines such as interferon-gamma, which can help coordinate the immune response and activate other immune cells.

CD8+ T cells are generated in the thymus gland and are a type of T cell, which is a lymphocyte that matures in the thymus and plays a central role in cell-mediated immunity. They recognize and respond to specific antigens presented on the surface of infected or cancerous cells in conjunction with major histocompatibility complex (MHC) class I molecules.

Overall, CD8+ T cells are an essential component of the immune system's defense against viral infections and cancer.

Leukemia L1210 is not a medical definition itself, but it refers to a specific mouse leukemia cell line that was established in 1948. These cells are a type of acute myeloid leukemia (AML) and have been widely used in cancer research as a model for studying the disease, testing new therapies, and understanding the biology of leukemia. The L1210 cell line has contributed significantly to the development of various chemotherapeutic agents and treatment strategies for leukemia and other cancers.

CD (cluster of differentiation) antigens are cell-surface proteins that are expressed on leukocytes (white blood cells) and can be used to identify and distinguish different subsets of these cells. They are important markers in the field of immunology and hematology, and are commonly used to diagnose and monitor various diseases, including cancer, autoimmune disorders, and infectious diseases.

CD antigens are designated by numbers, such as CD4, CD8, CD19, etc., which refer to specific proteins found on the surface of different types of leukocytes. For example, CD4 is a protein found on the surface of helper T cells, while CD8 is found on cytotoxic T cells.

CD antigens can be used as targets for immunotherapy, such as monoclonal antibody therapy, in which antibodies are designed to bind to specific CD antigens and trigger an immune response against cancer cells or infected cells. They can also be used as markers to monitor the effectiveness of treatments and to detect minimal residual disease (MRD) after treatment.

It's important to note that not all CD antigens are exclusive to leukocytes, some can be found on other cell types as well, and their expression can vary depending on the activation state or differentiation stage of the cells.

An epitope is a specific region on an antigen (a substance that triggers an immune response) that is recognized and bound by an antibody or a T-cell receptor. In the case of T-lymphocytes, which are a type of white blood cell that plays a central role in cell-mediated immunity, epitopes are typically presented on the surface of infected cells in association with major histocompatibility complex (MHC) molecules.

T-lymphocytes recognize and respond to epitopes through their T-cell receptors (TCRs), which are membrane-bound proteins that can bind to specific epitopes presented on the surface of infected cells. There are two main types of T-lymphocytes: CD4+ T-cells, also known as helper T-cells, and CD8+ T-cells, also known as cytotoxic T-cells.

CD4+ T-cells recognize epitopes presented in the context of MHC class II molecules, which are typically expressed on the surface of professional antigen-presenting cells such as dendritic cells, macrophages, and B-cells. CD4+ T-cells help to coordinate the immune response by producing cytokines that activate other immune cells.

CD8+ T-cells recognize epitopes presented in the context of MHC class I molecules, which are expressed on the surface of almost all nucleated cells. CD8+ T-cells are able to directly kill infected cells by releasing cytotoxic granules that contain enzymes that can induce apoptosis (programmed cell death) in the target cell.

In summary, epitopes are specific regions on antigens that are recognized and bound by T-lymphocytes through their T-cell receptors. CD4+ T-cells recognize epitopes presented in the context of MHC class II molecules, while CD8+ T-cells recognize epitopes presented in the context of MHC class I molecules.

Bovine Leukemia Virus (BLV) is a retrovirus that infects cattle and causes enzootic bovine leukosis, a neoplastic disease characterized by the proliferation of malignant B-lymphocytes. The virus primarily targets the animal's immune system, leading to a decrease in the number of white blood cells (leukopenia) and an increased susceptibility to other infections.

The virus is transmitted horizontally through close contact with infected animals or vertically from mother to offspring via infected milk or colostrum. The majority of BLV-infected cattle remain asymptomatic carriers, but a small percentage develop clinical signs such as lymphoma, weight loss, and decreased milk production.

BLV is closely related to human T-cell leukemia virus (HTLV), and both viruses belong to the Retroviridae family, genus Deltaretrovirus. However, it's important to note that BLV does not cause leukemia or any other neoplastic diseases in humans.

Feline Leukemia Virus (FeLV) is a retrovirus that primarily infects cats, causing a variety of diseases and disorders. It is the causative agent of feline leukemia, a name given to a syndrome characterized by a variety of symptoms such as lymphoma (cancer of the lymphatic system), anemia, immunosuppression, and reproductive disorders. FeLV is typically transmitted through close contact with infected cats, such as through saliva, nasal secretions, urine, and milk. It can also be spread through shared litter boxes and feeding dishes.

FeLV infects cells of the immune system, leading to a weakened immune response and making the cat more susceptible to other infections. The virus can also integrate its genetic material into the host's DNA, potentially causing cancerous changes in infected cells. FeLV is a significant health concern for cats, particularly those that are exposed to outdoor environments or come into contact with other cats. Vaccination and regular veterinary care can help protect cats from this virus.

A clone is a group of cells that are genetically identical to each other because they are derived from a common ancestor cell through processes such as mitosis or asexual reproduction. Therefore, the term "clone cells" refers to a population of cells that are genetic copies of a single parent cell.

In the context of laboratory research, cells can be cloned by isolating a single cell and allowing it to divide in culture, creating a population of genetically identical cells. This is useful for studying the behavior and characteristics of individual cell types, as well as for generating large quantities of cells for use in experiments.

It's important to note that while clone cells are genetically identical, they may still exhibit differences in their phenotype (physical traits) due to epigenetic factors or environmental influences.

Cell differentiation is the process by which a less specialized cell, or stem cell, becomes a more specialized cell type with specific functions and structures. This process involves changes in gene expression, which are regulated by various intracellular signaling pathways and transcription factors. Differentiation results in the development of distinct cell types that make up tissues and organs in multicellular organisms. It is a crucial aspect of embryonic development, tissue repair, and maintenance of homeostasis in the body.

1. Receptors: In the context of physiology and medicine, receptors are specialized proteins found on the surface of cells or inside cells that detect and respond to specific molecules, known as ligands. Receptors play a crucial role in signal transduction, enabling cells to communicate with each other and respond to changes in their environment.
2. Antigen: An antigen is any substance (usually a protein) that can be recognized by the immune system and stimulate an immune response. Antigens can be foreign substances such as bacteria, viruses, or pollen, or they can be components of our own cells, such as tumor antigens in cancer cells. Antigens are typically bound and presented to the immune system by specialized cells called antigen-presenting cells (APCs).
3. T-Cell: T-cells, also known as T lymphocytes, are a type of white blood cell that plays a central role in cell-mediated immunity. T-cells are produced in the bone marrow and mature in the thymus gland. There are two main types of T-cells: CD4+ helper T-cells and CD8+ cytotoxic T-cells. Helper T-cells assist other immune cells, such as B-cells and macrophages, in mounting an immune response, while cytotoxic T-cells directly kill infected or cancerous cells.
4. Alpha-Beta: Alpha-beta is a type of T-cell receptor (TCR) that is found on the surface of most mature T-cells. The alpha-beta TCR is composed of two polypeptide chains, an alpha chain and a beta chain, that are held together by disulfide bonds. The alpha-beta TCR recognizes and binds to specific antigens presented in the context of major histocompatibility complex (MHC) molecules on the surface of APCs. This interaction is critical for initiating an immune response against infected or cancerous cells.

A "knockout" mouse is a genetically engineered mouse in which one or more genes have been deleted or "knocked out" using molecular biology techniques. This allows researchers to study the function of specific genes and their role in various biological processes, as well as potential associations with human diseases. The mice are generated by introducing targeted DNA modifications into embryonic stem cells, which are then used to create a live animal. Knockout mice have been widely used in biomedical research to investigate gene function, disease mechanisms, and potential therapeutic targets.

The spleen is an organ in the upper left side of the abdomen, next to the stomach and behind the ribs. It plays multiple supporting roles in the body:

1. It fights infection by acting as a filter for the blood. Old red blood cells are recycled in the spleen, and platelets and white blood cells are stored there.
2. The spleen also helps to control the amount of blood in the body by removing excess red blood cells and storing platelets.
3. It has an important role in immune function, producing antibodies and removing microorganisms and damaged red blood cells from the bloodstream.

The spleen can be removed without causing any significant problems, as other organs take over its functions. This is known as a splenectomy and may be necessary if the spleen is damaged or diseased.

B-lymphocytes, also known as B-cells, are a type of white blood cell that plays a key role in the immune system's response to infection. They are responsible for producing antibodies, which are proteins that help to neutralize or destroy pathogens such as bacteria and viruses.

When a B-lymphocyte encounters a pathogen, it becomes activated and begins to divide and differentiate into plasma cells, which produce and secrete large amounts of antibodies specific to the antigens on the surface of the pathogen. These antibodies bind to the pathogen, marking it for destruction by other immune cells such as neutrophils and macrophages.

B-lymphocytes also have a role in presenting antigens to T-lymphocytes, another type of white blood cell involved in the immune response. This helps to stimulate the activation and proliferation of T-lymphocytes, which can then go on to destroy infected cells or help to coordinate the overall immune response.

Overall, B-lymphocytes are an essential part of the adaptive immune system, providing long-lasting immunity to previously encountered pathogens and helping to protect against future infections.

The thymus gland is an essential organ of the immune system, located in the upper chest, behind the sternum and surrounding the heart. It's primarily active until puberty and begins to shrink in size and activity thereafter. The main function of the thymus gland is the production and maturation of T-lymphocytes (T-cells), which are crucial for cell-mediated immunity, helping to protect the body from infection and cancer.

The thymus gland provides a protected environment where immune cells called pre-T cells develop into mature T cells. During this process, they learn to recognize and respond appropriately to foreign substances while remaining tolerant to self-tissues, which is crucial for preventing autoimmune diseases.

Additionally, the thymus gland produces hormones like thymosin that regulate immune cell activities and contribute to the overall immune response.

Gene expression regulation in leukemia refers to the processes that control the production or activation of specific proteins encoded by genes in leukemic cells. These regulatory mechanisms include various molecular interactions that can either promote or inhibit gene transcription and translation. In leukemia, abnormal gene expression regulation can lead to uncontrolled proliferation, differentiation arrest, and accumulation of malignant white blood cells (leukemia cells) in the bone marrow and peripheral blood.

Dysregulated gene expression in leukemia may involve genetic alterations such as mutations, chromosomal translocations, or epigenetic changes that affect DNA methylation patterns and histone modifications. These changes can result in the overexpression of oncogenes (genes with cancer-promoting functions) or underexpression of tumor suppressor genes (genes that prevent uncontrolled cell growth).

Understanding gene expression regulation in leukemia is crucial for developing targeted therapies and improving diagnostic, prognostic, and treatment strategies.

Adoptive transfer is a medical procedure in which immune cells are transferred from a donor to a recipient with the aim of providing immunity or treating a disease, such as cancer. This technique is often used in the field of immunotherapy and involves isolating specific immune cells (like T-cells) from the donor, expanding their numbers in the laboratory, and then infusing them into the patient. The transferred cells are expected to recognize and attack the target cells, such as malignant or infected cells, leading to a therapeutic effect. This process requires careful matching of donor and recipient to minimize the risk of rejection and graft-versus-host disease.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

A cell line is a culture of cells that are grown in a laboratory for use in research. These cells are usually taken from a single cell or group of cells, and they are able to divide and grow continuously in the lab. Cell lines can come from many different sources, including animals, plants, and humans. They are often used in scientific research to study cellular processes, disease mechanisms, and to test new drugs or treatments. Some common types of human cell lines include HeLa cells (which come from a cancer patient named Henrietta Lacks), HEK293 cells (which come from embryonic kidney cells), and HUVEC cells (which come from umbilical vein endothelial cells). It is important to note that cell lines are not the same as primary cells, which are cells that are taken directly from a living organism and have not been grown in the lab.

Cytokines are a broad and diverse category of small signaling proteins that are secreted by various cells, including immune cells, in response to different stimuli. They play crucial roles in regulating the immune response, inflammation, hematopoiesis, and cellular communication.

Cytokines mediate their effects by binding to specific receptors on the surface of target cells, which triggers intracellular signaling pathways that ultimately result in changes in gene expression, cell behavior, and function. Some key functions of cytokines include:

1. Regulating the activation, differentiation, and proliferation of immune cells such as T cells, B cells, natural killer (NK) cells, and macrophages.
2. Coordinating the inflammatory response by recruiting immune cells to sites of infection or tissue damage and modulating their effector functions.
3. Regulating hematopoiesis, the process of blood cell formation in the bone marrow, by controlling the proliferation, differentiation, and survival of hematopoietic stem and progenitor cells.
4. Modulating the development and function of the nervous system, including neuroinflammation, neuroprotection, and neuroregeneration.

Cytokines can be classified into several categories based on their structure, function, or cellular origin. Some common types of cytokines include interleukins (ILs), interferons (IFNs), tumor necrosis factors (TNFs), chemokines, colony-stimulating factors (CSFs), and transforming growth factors (TGFs). Dysregulation of cytokine production and signaling has been implicated in various pathological conditions, such as autoimmune diseases, chronic inflammation, cancer, and neurodegenerative disorders.

C57BL/6 (C57 Black 6) is an inbred strain of laboratory mouse that is widely used in biomedical research. The term "inbred" refers to a strain of animals where matings have been carried out between siblings or other closely related individuals for many generations, resulting in a population that is highly homozygous at most genetic loci.

The C57BL/6 strain was established in 1920 by crossing a female mouse from the dilute brown (DBA) strain with a male mouse from the black strain. The resulting offspring were then interbred for many generations to create the inbred C57BL/6 strain.

C57BL/6 mice are known for their robust health, longevity, and ease of handling, making them a popular choice for researchers. They have been used in a wide range of biomedical research areas, including studies of cancer, immunology, neuroscience, cardiovascular disease, and metabolism.

One of the most notable features of the C57BL/6 strain is its sensitivity to certain genetic modifications, such as the introduction of mutations that lead to obesity or impaired glucose tolerance. This has made it a valuable tool for studying the genetic basis of complex diseases and traits.

Overall, the C57BL/6 inbred mouse strain is an important model organism in biomedical research, providing a valuable resource for understanding the genetic and molecular mechanisms underlying human health and disease.

Dendritic cells (DCs) are a type of immune cell that play a critical role in the body's defense against infection and cancer. They are named for their dendrite-like projections, which they use to interact with and sample their environment. DCs are responsible for processing antigens (foreign substances that trigger an immune response) and presenting them to T cells, a type of white blood cell that plays a central role in the immune system's response to infection and cancer.

DCs can be found throughout the body, including in the skin, mucous membranes, and lymphoid organs. They are able to recognize and respond to a wide variety of antigens, including those from bacteria, viruses, fungi, and parasites. Once they have processed an antigen, DCs migrate to the lymph nodes, where they present the antigen to T cells. This interaction activates the T cells, which then go on to mount a targeted immune response against the invading pathogen or cancerous cells.

DCs are a diverse group of cells that can be divided into several subsets based on their surface markers and function. Some DCs, such as Langerhans cells and dermal DCs, are found in the skin and mucous membranes, where they serve as sentinels for invading pathogens. Other DCs, such as plasmacytoid DCs and conventional DCs, are found in the lymphoid organs, where they play a role in activating T cells and initiating an immune response.

Overall, dendritic cells are essential for the proper functioning of the immune system, and dysregulation of these cells has been implicated in a variety of diseases, including autoimmune disorders and cancer.

Radiation-induced leukemia is a type of cancer that affects the blood-forming tissues of the body, such as the bone marrow. It is caused by exposure to high levels of radiation, which can damage the DNA of cells and lead to their uncontrolled growth and division.

There are several types of radiation-induced leukemia, depending on the specific type of blood cell that becomes cancerous. The most common types are acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). These forms of leukemia tend to progress quickly and require prompt treatment.

Radiation-induced leukemia is a rare complication of radiation therapy, which is used to treat many types of cancer. The risk of developing this type of leukemia increases with the dose and duration of radiation exposure. It is important to note that the benefits of radiation therapy in treating cancer generally outweigh the small increased risk of developing radiation-induced leukemia.

Symptoms of radiation-induced leukemia may include fatigue, fever, frequent infections, easy bruising or bleeding, and weight loss. If you have been exposed to high levels of radiation and are experiencing these symptoms, it is important to seek medical attention promptly. A diagnosis of radiation-induced leukemia is typically made through a combination of physical exam, medical history, and laboratory tests, such as blood counts and bone marrow biopsy. Treatment may include chemotherapy, radiation therapy, and/or stem cell transplantation.

The Myeloid-Lymphoid Leukemia (MLL) protein, also known as MLL1 or HRX, is a histone methyltransferase that plays a crucial role in the regulation of gene expression. It is involved in various cellular processes, including embryonic development and hematopoiesis (the formation of blood cells).

The MLL protein is encoded by the MLL gene, which is located on chromosome 11q23. This gene is frequently rearranged or mutated in certain types of leukemia, leading to the production of abnormal fusion proteins that contribute to tumor development and progression. These MLL-rearranged leukemias are aggressive and have a poor prognosis, making them an important area of research in the field of oncology.

1. Receptors: In the context of physiology and medicine, receptors are specialized proteins found on the surface of cells or inside cells that detect and respond to specific molecules, known as ligands. They play a crucial role in various biological processes, including signal transduction, cell communication, and regulation of physiological functions.
2. Antigen: An antigen is a foreign substance (usually a protein) that triggers an immune response when introduced into the body. Antigens can be derived from various sources, such as bacteria, viruses, fungi, or parasites. They are recognized by the immune system as non-self and stimulate the production of antibodies and activation of immune cells, like T-cells, to eliminate the threat.
3. T-Cell: T-cells, also known as T-lymphocytes, are a type of white blood cell that plays a central role in cell-mediated immunity. They are produced in the bone marrow and mature in the thymus gland. T-cells have receptors on their surface called T-cell receptors (TCRs) that enable them to recognize and respond to specific antigens presented by antigen-presenting cells (APCs). There are several types of T-cells, including CD4+ helper T-cells, CD8+ cytotoxic T-cells, and regulatory T-cells.
4. gamma-delta (γδ) T-Cell: Gamma-delta (γδ) T-cells are a subset of T-cells that possess a distinct T-cell receptor (TCR) composed of gamma and delta chains. Unlike conventional T-cells, which typically recognize peptide antigens presented by major histocompatibility complex (MHC) molecules, γδ T-cells can directly recognize various non-peptide antigens, such as lipids, glycolipids, and small metabolites. They are involved in the early stages of immune responses, tissue homeostasis, and cancer surveillance.

Monoclonal antibodies are a type of antibody that are identical because they are produced by a single clone of cells. They are laboratory-produced molecules that act like human antibodies in the immune system. They can be designed to attach to specific proteins found on the surface of cancer cells, making them useful for targeting and treating cancer. Monoclonal antibodies can also be used as a therapy for other diseases, such as autoimmune disorders and inflammatory conditions.

Monoclonal antibodies are produced by fusing a single type of immune cell, called a B cell, with a tumor cell to create a hybrid cell, or hybridoma. This hybrid cell is then able to replicate indefinitely, producing a large number of identical copies of the original antibody. These antibodies can be further modified and engineered to enhance their ability to bind to specific targets, increase their stability, and improve their effectiveness as therapeutic agents.

Monoclonal antibodies have several mechanisms of action in cancer therapy. They can directly kill cancer cells by binding to them and triggering an immune response. They can also block the signals that promote cancer growth and survival. Additionally, monoclonal antibodies can be used to deliver drugs or radiation directly to cancer cells, increasing the effectiveness of these treatments while minimizing their side effects on healthy tissues.

Monoclonal antibodies have become an important tool in modern medicine, with several approved for use in cancer therapy and other diseases. They are continuing to be studied and developed as a promising approach to treating a wide range of medical conditions.

Immunologic cytotoxicity refers to the damage or destruction of cells that occurs as a result of an immune response. This process involves the activation of immune cells, such as cytotoxic T cells and natural killer (NK) cells, which release toxic substances, such as perforins and granzymes, that can kill target cells.

In addition, antibodies produced by B cells can also contribute to immunologic cytotoxicity by binding to antigens on the surface of target cells and triggering complement-mediated lysis or antibody-dependent cellular cytotoxicity (ADCC) by activating immune effector cells.

Immunologic cytotoxicity plays an important role in the body's defense against viral infections, cancer cells, and other foreign substances. However, it can also contribute to tissue damage and autoimmune diseases if the immune system mistakenly targets healthy cells or tissues.

I'm sorry for any confusion, but "Leukemia P388" is not a widely recognized medical term or a specific type of leukemia. The term "P388" is often used to refer to a particular type of mouse leukemia that is commonly used in laboratory research for testing potential anti-cancer drugs.

Leukemia, in general, is a type of cancer that originates in the bone marrow and results in an overproduction of abnormal white blood cells (leukocytes). These abnormal cells crowd out the healthy cells in the bone marrow, leading to a weakened immune system and various complications.

There are many different types of leukemia, classified based on the type of white blood cell affected (myeloid or lymphocytic) and the speed of progression (acute or chronic). If you're looking for information about a specific type of leukemia, I would be happy to help if you could provide more details.

Signal transduction is the process by which a cell converts an extracellular signal, such as a hormone or neurotransmitter, into an intracellular response. This involves a series of molecular events that transmit the signal from the cell surface to the interior of the cell, ultimately resulting in changes in gene expression, protein activity, or metabolism.

The process typically begins with the binding of the extracellular signal to a receptor located on the cell membrane. This binding event activates the receptor, which then triggers a cascade of intracellular signaling molecules, such as second messengers, protein kinases, and ion channels. These molecules amplify and propagate the signal, ultimately leading to the activation or inhibition of specific cellular responses.

Signal transduction pathways are highly regulated and can be modulated by various factors, including other signaling molecules, post-translational modifications, and feedback mechanisms. Dysregulation of these pathways has been implicated in a variety of diseases, including cancer, diabetes, and neurological disorders.

Cell proliferation is the process by which cells increase in number, typically through the process of cell division. In the context of biology and medicine, it refers to the reproduction of cells that makes up living tissue, allowing growth, maintenance, and repair. It involves several stages including the transition from a phase of quiescence (G0 phase) to an active phase (G1 phase), DNA replication in the S phase, and mitosis or M phase, where the cell divides into two daughter cells.

Abnormal or uncontrolled cell proliferation is a characteristic feature of many diseases, including cancer, where deregulated cell cycle control leads to excessive and unregulated growth of cells, forming tumors that can invade surrounding tissues and metastasize to distant sites in the body.

Cytotoxic T-lymphocytes, also known as CD8+ T cells, are a type of white blood cell that plays a central role in the cell-mediated immune system. They are responsible for identifying and destroying virus-infected cells and cancer cells. When a cytotoxic T-lymphocyte recognizes a specific antigen presented on the surface of an infected or malignant cell, it becomes activated and releases toxic substances such as perforins and granzymes, which can create pores in the target cell's membrane and induce apoptosis (programmed cell death). This process helps to eliminate the infected or malignant cells and prevent the spread of infection or cancer.

Adult T-cell Leukemia/Lymphoma (ATLL) is a rare and aggressive type of cancer that affects the circulating white blood cells called T-lymphocytes or T-cells. It is caused by the human T-cell leukemia virus type 1 (HTLV-1), which infects CD4+ T-cells and leads to their malignant transformation. The disease can present as either acute or chronic leukemia, or as lymphoma, depending on the clinical features and laboratory findings.

The acute form of ATLL is characterized by the rapid proliferation of abnormal T-cells in the blood, bone marrow, and other organs. Patients with acute ATLL typically have a poor prognosis, with a median survival of only a few months. Symptoms may include skin rashes, lymphadenopathy (swollen lymph nodes), hepatosplenomegaly (enlarged liver and spleen), and hypercalcemia (high levels of calcium in the blood).

The chronic form of ATLL is less aggressive than the acute form, but it can still lead to serious complications. Chronic ATLL is characterized by the accumulation of abnormal T-cells in the blood and lymph nodes, as well as skin lesions and hypercalcemia. The median survival for patients with chronic ATLL is around two years.

ATLL can also present as a lymphoma, which is characterized by the proliferation of abnormal T-cells in the lymph nodes, spleen, and other organs. Lymphoma may occur in isolation or in combination with leukemic features.

The diagnosis of ATLL is based on clinical findings, laboratory tests, and the detection of HTLV-1 antibodies or proviral DNA in the blood or tissue samples. Treatment options for ATLL include chemotherapy, antiretroviral therapy, immunotherapy, and stem cell transplantation. The choice of treatment depends on several factors, including the patient's age, overall health, and the stage and type of ATLL.

CD28 is a co-stimulatory molecule that plays an important role in the activation and regulation of T cells, which are key players in the immune response. It is a type of protein found on the surface of T cells and interacts with other proteins called B7-1 (also known as CD80) and B7-2 (also known as CD86) that are expressed on the surface of antigen-presenting cells (APCs).

When a T cell encounters an APC that is presenting an antigen, the T cell receptor (TCR) on the surface of the T cell recognizes and binds to the antigen. However, this interaction alone is not enough to fully activate the T cell. The engagement of CD28 with B7-1 or B7-2 provides a critical co-stimulatory signal that promotes T cell activation, proliferation, and survival.

CD28 is also an important target for immune checkpoint inhibitors, which are drugs used to treat cancer by blocking the inhibitory signals that prevent T cells from attacking tumor cells. By blocking CD28, these drugs can enhance the anti-tumor response of T cells and improve cancer outcomes.

Immune tolerance, also known as immunological tolerance or specific immune tolerance, is a state of unresponsiveness or non-reactivity of the immune system towards a particular substance (antigen) that has the potential to elicit an immune response. This occurs when the immune system learns to distinguish "self" from "non-self" and does not attack the body's own cells, tissues, and organs.

In the context of transplantation, immune tolerance refers to the absence of a destructive immune response towards the transplanted organ or tissue, allowing for long-term graft survival without the need for immunosuppressive therapy. Immune tolerance can be achieved through various strategies, including hematopoietic stem cell transplantation, costimulation blockade, and regulatory T cell induction.

In summary, immune tolerance is a critical mechanism that prevents the immune system from attacking the body's own structures while maintaining the ability to respond appropriately to foreign pathogens and antigens.

A lymphocyte count is a laboratory test that measures the number of white blood cells called lymphocytes in a sample of blood. Lymphocytes are a vital part of the immune system and help fight off infections and diseases. A normal lymphocyte count ranges from 1,000 to 4,800 cells per microliter (µL) of blood for adults.

An abnormal lymphocyte count can indicate an infection, immune disorder, or blood cancer. A low lymphocyte count is called lymphopenia, while a high lymphocyte count is called lymphocytosis. The cause of an abnormal lymphocyte count should be investigated through further testing and clinical evaluation.

CD4 antigens, also known as CD4 proteins or CD4 molecules, are a type of cell surface receptor found on certain immune cells, including T-helper cells and monocytes. They play a critical role in the immune response by binding to class II major histocompatibility complex (MHC) molecules on the surface of antigen-presenting cells and helping to activate T-cells. CD4 antigens are also the primary target of the human immunodeficiency virus (HIV), which causes AIDS, leading to the destruction of CD4-positive T-cells and a weakened immune system.

Apoptosis is a programmed and controlled cell death process that occurs in multicellular organisms. It is a natural process that helps maintain tissue homeostasis by eliminating damaged, infected, or unwanted cells. During apoptosis, the cell undergoes a series of morphological changes, including cell shrinkage, chromatin condensation, and fragmentation into membrane-bound vesicles called apoptotic bodies. These bodies are then recognized and engulfed by neighboring cells or phagocytic cells, preventing an inflammatory response. Apoptosis is regulated by a complex network of intracellular signaling pathways that involve proteins such as caspases, Bcl-2 family members, and inhibitors of apoptosis (IAPs).

Friend murine leukemia virus (F-MuLV) is a type of retrovirus that specifically infects mice. It was first discovered by Charlotte Friend in the 1950s and has since been widely used as a model system to study retroviral pathogenesis, oncogenesis, and immune responses.

F-MuLV is a complex retrovirus that contains several accessory genes, including gag, pol, env, and others. The virus can cause leukemia and other malignancies in susceptible mice, particularly when it is transmitted from mother to offspring through the milk.

The virus is also known to induce immunosuppression, which makes infected mice more susceptible to other infections and diseases. F-MuLV has been used extensively in laboratory research to investigate various aspects of retroviral biology, including viral entry, replication, gene expression, and host immune responses.

It is important to note that Friend murine leukemia virus only infects mice and is not known to cause any disease in humans or other animals.

Biphenotypic acute leukemia (BAL) is a rare subtype of acute leukemia that possesses the features of both myeloid and lymphoid lineages. It is characterized by the presence of blasts that express antigens associated with both cell lines, which can make it challenging to diagnose and treat. BAL is considered an aggressive form of leukemia and requires prompt medical attention and treatment. The exact cause of BAL is not well understood, but like other forms of leukemia, it is thought to result from genetic mutations that lead to uncontrolled cell growth and division.

Antigens are substances (usually proteins) on the surface of cells, viruses, fungi, or bacteria that the immune system recognizes as foreign and mounts a response against.

Differentiation in the context of T-lymphocytes refers to the process by which immature T-cells mature and develop into different types of T-cells with specific functions, such as CD4+ helper T-cells or CD8+ cytotoxic T-cells.

T-lymphocytes, also known as T-cells, are a type of white blood cell that plays a central role in cell-mediated immunity. They are produced in the bone marrow and mature in the thymus gland. Once mature, they circulate throughout the body in search of foreign antigens to attack and destroy.

Therefore, 'Antigens, Differentiation, T-Lymphocyte' refers to the process by which T-lymphocytes mature and develop the ability to recognize and respond to specific foreign antigens.

An acute disease is a medical condition that has a rapid onset, develops quickly, and tends to be short in duration. Acute diseases can range from minor illnesses such as a common cold or flu, to more severe conditions such as pneumonia, meningitis, or a heart attack. These types of diseases often have clear symptoms that are easy to identify, and they may require immediate medical attention or treatment.

Acute diseases are typically caused by an external agent or factor, such as a bacterial or viral infection, a toxin, or an injury. They can also be the result of a sudden worsening of an existing chronic condition. In general, acute diseases are distinct from chronic diseases, which are long-term medical conditions that develop slowly over time and may require ongoing management and treatment.

Examples of acute diseases include:

* Acute bronchitis: a sudden inflammation of the airways in the lungs, often caused by a viral infection.
* Appendicitis: an inflammation of the appendix that can cause severe pain and requires surgical removal.
* Gastroenteritis: an inflammation of the stomach and intestines, often caused by a viral or bacterial infection.
* Migraine headaches: intense headaches that can last for hours or days, and are often accompanied by nausea, vomiting, and sensitivity to light and sound.
* Myocardial infarction (heart attack): a sudden blockage of blood flow to the heart muscle, often caused by a buildup of plaque in the coronary arteries.
* Pneumonia: an infection of the lungs that can cause coughing, chest pain, and difficulty breathing.
* Sinusitis: an inflammation of the sinuses, often caused by a viral or bacterial infection.

It's important to note that while some acute diseases may resolve on their own with rest and supportive care, others may require medical intervention or treatment to prevent complications and promote recovery. If you are experiencing symptoms of an acute disease, it is always best to seek medical attention to ensure proper diagnosis and treatment.

Lymphocyte activation is the process by which B-cells and T-cells (types of lymphocytes) become activated to perform effector functions in an immune response. This process involves the recognition of specific antigens presented on the surface of antigen-presenting cells, such as dendritic cells or macrophages.

The activation of B-cells leads to their differentiation into plasma cells that produce antibodies, while the activation of T-cells results in the production of cytotoxic T-cells (CD8+ T-cells) that can directly kill infected cells or helper T-cells (CD4+ T-cells) that assist other immune cells.

Lymphocyte activation involves a series of intracellular signaling events, including the binding of co-stimulatory molecules and the release of cytokines, which ultimately result in the expression of genes involved in cell proliferation, differentiation, and effector functions. The activation process is tightly regulated to prevent excessive or inappropriate immune responses that can lead to autoimmunity or chronic inflammation.

'Tumor cells, cultured' refers to the process of removing cancerous cells from a tumor and growing them in controlled laboratory conditions. This is typically done by isolating the tumor cells from a patient's tissue sample, then placing them in a nutrient-rich environment that promotes their growth and multiplication.

The resulting cultured tumor cells can be used for various research purposes, including the study of cancer biology, drug development, and toxicity testing. They provide a valuable tool for researchers to better understand the behavior and characteristics of cancer cells outside of the human body, which can lead to the development of more effective cancer treatments.

It is important to note that cultured tumor cells may not always behave exactly the same way as they do in the human body, so findings from cell culture studies must be validated through further research, such as animal models or clinical trials.

CD45 is a protein that is found on the surface of many types of white blood cells, including T-cells, B-cells, and natural killer (NK) cells. It is also known as leukocyte common antigen because it is present on almost all leukocytes. CD45 is a tyrosine phosphatase that plays a role in regulating the activity of various proteins involved in cell signaling pathways.

As an antigen, CD45 is used as a marker to identify and distinguish different types of white blood cells. It has several isoforms that are generated by alternative splicing of its mRNA, resulting in different molecular weights. The size of the CD45 isoform can be used to distinguish between different subsets of T-cells and B-cells.

CD45 is an important molecule in the immune system, and abnormalities in its expression or function have been implicated in various diseases, including autoimmune disorders and cancer.

Forkhead transcription factors (FOX) are a family of proteins that play crucial roles in the regulation of gene expression through the process of binding to specific DNA sequences, thereby controlling various biological processes such as cell growth, differentiation, and apoptosis. These proteins are characterized by a conserved DNA-binding domain, known as the forkhead box or FOX domain, which adopts a winged helix structure that recognizes and binds to the consensus sequence 5'-(G/A)(T/C)AA(C/A)A-3'.

The FOX family is further divided into subfamilies based on the structure of their DNA-binding domains, with each subfamily having distinct functions. For example, FOXP proteins are involved in brain development and function, while FOXO proteins play a key role in regulating cellular responses to stress and metabolism. Dysregulation of forkhead transcription factors has been implicated in various diseases, including cancer, diabetes, and neurodegenerative disorders.

Bone marrow is the spongy tissue found inside certain bones in the body, such as the hips, thighs, and vertebrae. It is responsible for producing blood-forming cells, including red blood cells, white blood cells, and platelets. There are two types of bone marrow: red marrow, which is involved in blood cell production, and yellow marrow, which contains fatty tissue.

Red bone marrow contains hematopoietic stem cells, which can differentiate into various types of blood cells. These stem cells continuously divide and mature to produce new blood cells that are released into the circulation. Red blood cells carry oxygen throughout the body, white blood cells help fight infections, and platelets play a crucial role in blood clotting.

Bone marrow also serves as a site for immune cell development and maturation. It contains various types of immune cells, such as lymphocytes, macrophages, and dendritic cells, which help protect the body against infections and diseases.

Abnormalities in bone marrow function can lead to several medical conditions, including anemia, leukopenia, thrombocytopenia, and various types of cancer, such as leukemia and multiple myeloma. Bone marrow aspiration and biopsy are common diagnostic procedures used to evaluate bone marrow health and function.

Interleukin-2 (IL-2) receptors are a type of cell surface receptor that bind to and interact with the cytokine interleukin-2. IL-2 is a protein that plays an important role in the immune system, particularly in the activation and proliferation of T cells, a type of white blood cell that helps protect the body from infection and disease.

IL-2 receptors are composed of three subunits: alpha (CD25), beta (CD122), and gamma (CD132). These subunits can combine to form different types of IL-2 receptors, each with different functions. The high-affinity IL-2 receptor is made up of all three subunits and is found on the surface of activated T cells. This type of receptor has a strong binding affinity for IL-2 and plays a crucial role in T cell activation and proliferation.

The intermediate-affinity IL-2 receptor, which consists of the beta and gamma subunits, is found on the surface of resting T cells and natural killer (NK) cells. This type of receptor has a lower binding affinity for IL-2 and plays a role in activating and proliferating these cells.

IL-2 receptors are important targets for immunotherapy, as they play a key role in the regulation of the immune response. Drugs that target IL-2 receptors, such as aldesleukin (Proleukin), have been used to treat certain types of cancer and autoimmune diseases.

A base sequence in the context of molecular biology refers to the specific order of nucleotides in a DNA or RNA molecule. In DNA, these nucleotides are adenine (A), guanine (G), cytosine (C), and thymine (T). In RNA, uracil (U) takes the place of thymine. The base sequence contains genetic information that is transcribed into RNA and ultimately translated into proteins. It is the exact order of these bases that determines the genetic code and thus the function of the DNA or RNA molecule.

HL-60 cells are a type of human promyelocytic leukemia cell line that is commonly used in scientific research. They are named after the hospital where they were first isolated, the Hospital of the University of Pennsylvania (HUP) and the 60th culture attempt to grow these cells.

HL-60 cells have the ability to differentiate into various types of blood cells, such as granulocytes, monocytes, and macrophages, when exposed to certain chemical compounds or under specific culturing conditions. This makes them a valuable tool for studying the mechanisms of cell differentiation, proliferation, and apoptosis (programmed cell death).

HL-60 cells are also often used in toxicity studies, drug discovery and development, and research on cancer, inflammation, and infectious diseases. They can be easily grown in the lab and have a stable genotype, making them ideal for use in standardized experiments and comparisons between different studies.

An amino acid sequence is the specific order of amino acids in a protein or peptide molecule, formed by the linking of the amino group (-NH2) of one amino acid to the carboxyl group (-COOH) of another amino acid through a peptide bond. The sequence is determined by the genetic code and is unique to each type of protein or peptide. It plays a crucial role in determining the three-dimensional structure and function of proteins.

Membrane glycoproteins are proteins that contain oligosaccharide chains (glycans) covalently attached to their polypeptide backbone. They are integral components of biological membranes, spanning the lipid bilayer and playing crucial roles in various cellular processes.

The glycosylation of these proteins occurs in the endoplasmic reticulum (ER) and Golgi apparatus during protein folding and trafficking. The attached glycans can vary in structure, length, and composition, which contributes to the diversity of membrane glycoproteins.

Membrane glycoproteins can be classified into two main types based on their orientation within the lipid bilayer:

1. Type I (N-linked): These glycoproteins have a single transmembrane domain and an extracellular N-terminus, where the oligosaccharides are predominantly attached via asparagine residues (Asn-X-Ser/Thr sequon).
2. Type II (C-linked): These glycoproteins possess two transmembrane domains and an intracellular C-terminus, with the oligosaccharides linked to tryptophan residues via a mannose moiety.

Membrane glycoproteins are involved in various cellular functions, such as:

* Cell adhesion and recognition
* Receptor-mediated signal transduction
* Enzymatic catalysis
* Transport of molecules across membranes
* Cell-cell communication
* Immunological responses

Some examples of membrane glycoproteins include cell surface receptors (e.g., growth factor receptors, cytokine receptors), adhesion molecules (e.g., integrins, cadherins), and transporters (e.g., ion channels, ABC transporters).

Cell division is the process by which a single eukaryotic cell (a cell with a true nucleus) divides into two identical daughter cells. This complex process involves several stages, including replication of DNA, separation of chromosomes, and division of the cytoplasm. There are two main types of cell division: mitosis and meiosis.

Mitosis is the type of cell division that results in two genetically identical daughter cells. It is a fundamental process for growth, development, and tissue repair in multicellular organisms. The stages of mitosis include prophase, prometaphase, metaphase, anaphase, and telophase, followed by cytokinesis, which divides the cytoplasm.

Meiosis, on the other hand, is a type of cell division that occurs in the gonads (ovaries and testes) during the production of gametes (sex cells). Meiosis results in four genetically unique daughter cells, each with half the number of chromosomes as the parent cell. This process is essential for sexual reproduction and genetic diversity. The stages of meiosis include meiosis I and meiosis II, which are further divided into prophase, prometaphase, metaphase, anaphase, and telophase.

In summary, cell division is the process by which a single cell divides into two daughter cells, either through mitosis or meiosis. This process is critical for growth, development, tissue repair, and sexual reproduction in multicellular organisms.

Cytarabine is a chemotherapeutic agent used in the treatment of various types of cancer, including leukemias and lymphomas. Its chemical name is cytosine arabinoside, and it works by interfering with the DNA synthesis of cancer cells, which ultimately leads to their death.

Cytarabine is often used in combination with other chemotherapy drugs and may be administered through various routes, such as intravenous (IV) or subcutaneous injection, or orally. The specific dosage and duration of treatment will depend on the type and stage of cancer being treated, as well as the patient's overall health status.

Like all chemotherapy drugs, cytarabine can cause a range of side effects, including nausea, vomiting, diarrhea, hair loss, and an increased risk of infection. It may also cause more serious side effects, such as damage to the liver, kidneys, or nervous system, and it is important for patients to be closely monitored during treatment to minimize these risks.

It's important to note that medical treatments should only be administered under the supervision of a qualified healthcare professional, and this information should not be used as a substitute for medical advice.

Lymph nodes are small, bean-shaped organs that are part of the immune system. They are found throughout the body, especially in the neck, armpits, groin, and abdomen. Lymph nodes filter lymph fluid, which carries waste and unwanted substances such as bacteria, viruses, and cancer cells. They contain white blood cells called lymphocytes that help fight infections and diseases by attacking and destroying the harmful substances found in the lymph fluid. When an infection or disease is present, lymph nodes may swell due to the increased number of immune cells and fluid accumulation as they work to fight off the invaders.

T-lymphocytes, also known as T-cells, are a type of white blood cell that plays a key role in the immune response. They help to protect the body from infection and disease by identifying and attacking foreign substances such as viruses and bacteria.

Helper-inducer T-lymphocytes, also known as CD4+ T-cells or Th0 cells, are a specific subset of T-lymphocytes that help to coordinate the immune response. They do this by activating other immune cells, such as B-lymphocytes (which produce antibodies) and cytotoxic T-lymphocytes (which directly attack infected cells). Helper-inducer T-lymphocytes also release cytokines, which are signaling molecules that help to regulate the immune response.

Helper-inducer T-lymphocytes can differentiate into different subsets of T-cells, depending on the type of cytokines they are exposed to. For example, they can differentiate into Th1 cells, which produce cytokines that help to activate cytotoxic T-lymphocytes and macrophages; or Th2 cells, which produce cytokines that help to activate B-lymphocytes and eosinophils.

It is important to note that helper-inducer T-lymphocytes play a crucial role in the immune response, and dysfunction of these cells can lead to immunodeficiency or autoimmune disorders.

The Interleukin-2 Receptor alpha Subunit (IL-2Rα), also known as CD25, is a protein that is expressed on the surface of certain immune cells, such as activated T-cells and B-cells. It is a subunit of the interleukin-2 receptor, which plays a crucial role in the activation and regulation of the immune response. The IL-2Rα binds to interleukin-2 (IL-2) with high affinity, forming a complex that initiates intracellular signaling pathways involved in T-cell proliferation, differentiation, and survival. IL-2Rα is also a target for immunosuppressive therapies used to prevent rejection of transplanted organs and to treat autoimmune diseases.

Acute Megakaryoblastic Leukemia (AMKL) is a type of cancer that affects the blood and bone marrow. Specifically, it is a subtype of acute myeloid leukemia (AML), which is characterized by the rapid growth of abnormal cells in the bone marrow that interfere with the production of normal blood cells.

In AMKL, the abnormal cells are megakaryoblasts, which are immature cells that should develop into platelet-producing cells called megakaryocytes. However, in AMKL, these cells do not mature properly and instead accumulate in the bone marrow and bloodstream, leading to a shortage of healthy blood cells.

Symptoms of AMKL may include fatigue, weakness, frequent infections, easy bruising or bleeding, and the appearance of small red spots on the skin (petechiae). Diagnosis typically involves a combination of physical exam, medical history, blood tests, bone marrow aspiration and biopsy, and sometimes imaging studies.

Treatment for AMKL usually involves a combination of chemotherapy, radiation therapy, and/or stem cell transplantation. The specific treatment plan will depend on several factors, including the patient's age, overall health, and the extent of the disease.

Th1 cells, or Type 1 T helper cells, are a subset of CD4+ T cells that play a crucial role in the cell-mediated immune response. They are characterized by the production of specific cytokines, such as interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin-2 (IL-2). Th1 cells are essential for protecting against intracellular pathogens, including viruses, bacteria, and parasites. They activate macrophages to destroy ingested microorganisms, stimulate the differentiation of B cells into plasma cells that produce antibodies, and recruit other immune cells to the site of infection. Dysregulation of Th1 cell responses has been implicated in various autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes.

Antineoplastic agents are a class of drugs used to treat malignant neoplasms or cancer. These agents work by inhibiting the growth and proliferation of cancer cells, either by killing them or preventing their division and replication. Antineoplastic agents can be classified based on their mechanism of action, such as alkylating agents, antimetabolites, topoisomerase inhibitors, mitotic inhibitors, and targeted therapy agents.

Alkylating agents work by adding alkyl groups to DNA, which can cause cross-linking of DNA strands and ultimately lead to cell death. Antimetabolites interfere with the metabolic processes necessary for DNA synthesis and replication, while topoisomerase inhibitors prevent the relaxation of supercoiled DNA during replication. Mitotic inhibitors disrupt the normal functioning of the mitotic spindle, which is essential for cell division. Targeted therapy agents are designed to target specific molecular abnormalities in cancer cells, such as mutated oncogenes or dysregulated signaling pathways.

It's important to note that antineoplastic agents can also affect normal cells and tissues, leading to various side effects such as nausea, vomiting, hair loss, and myelosuppression (suppression of bone marrow function). Therefore, the use of these drugs requires careful monitoring and management of their potential adverse effects.

A fusion protein known as "BCR-ABL" is formed due to a genetic abnormality called the Philadelphia chromosome (derived from a reciprocal translocation between chromosomes 9 and 22). This results in the formation of the oncogenic BCR-ABL tyrosine kinase, which contributes to unregulated cell growth and division, leading to chronic myeloid leukemia (CML) and some types of acute lymphoblastic leukemia (ALL). The BCR-ABL fusion protein has constitutively active tyrosine kinase activity, which results in the activation of various signaling pathways promoting cell proliferation, survival, and inhibition of apoptosis. This genetic alteration is crucial in the development and progression of CML and some types of ALL, making BCR-ABL an important therapeutic target for these malignancies.

Histocompatibility antigens Class II are a group of cell surface proteins that play a crucial role in the immune system's response to foreign substances. They are expressed on the surface of various cells, including immune cells such as B lymphocytes, macrophages, dendritic cells, and activated T lymphocytes.

Class II histocompatibility antigens are encoded by the major histocompatibility complex (MHC) class II genes, which are located on chromosome 6 in humans. These antigens are composed of two non-covalently associated polypeptide chains, an alpha (α) and a beta (β) chain, which form a heterodimer. There are three main types of Class II histocompatibility antigens, known as HLA-DP, HLA-DQ, and HLA-DR.

Class II histocompatibility antigens present peptide antigens to CD4+ T helper cells, which then activate other immune cells, such as B cells and macrophages, to mount an immune response against the presented antigen. Because of their role in initiating an immune response, Class II histocompatibility antigens are important in transplantation medicine, where mismatches between donor and recipient can lead to rejection of the transplanted organ or tissue.

Neoplasm antigens, also known as tumor antigens, are substances that are produced by cancer cells (neoplasms) and can stimulate an immune response. These antigens can be proteins, carbohydrates, or other molecules that are either unique to the cancer cells or are overexpressed or mutated versions of normal cellular proteins.

Neoplasm antigens can be classified into two main categories: tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs). TSAs are unique to cancer cells and are not expressed by normal cells, while TAAs are present at low levels in normal cells but are overexpressed or altered in cancer cells.

TSAs can be further divided into viral antigens and mutated antigens. Viral antigens are produced when cancer is caused by a virus, such as human papillomavirus (HPV) in cervical cancer. Mutated antigens are the result of genetic mutations that occur during cancer development and are unique to each patient's tumor.

Neoplasm antigens play an important role in the immune response against cancer. They can be recognized by the immune system, leading to the activation of immune cells such as T cells and natural killer (NK) cells, which can then attack and destroy cancer cells. However, cancer cells often develop mechanisms to evade the immune response, allowing them to continue growing and spreading.

Understanding neoplasm antigens is important for the development of cancer immunotherapies, which aim to enhance the body's natural immune response against cancer. These therapies include checkpoint inhibitors, which block proteins that inhibit T cell activation, and therapeutic vaccines, which stimulate an immune response against specific tumor antigens.

The AKR murine leukemia virus (AKR MLV) is a type of retrovirus that naturally infects mice of the AKR strain. It is a member of the gammaretrovirus genus and is closely related to other murine leukemia viruses (MLVs).

AKR MLV is transmitted horizontally through close contact with infected animals, as well as vertically from mother to offspring. The virus primarily infects hematopoietic cells, including lymphocytes and macrophages, and can cause a variety of diseases, most notably leukemia and lymphoma.

The AKR MLV genome contains three main structural genes: gag, pol, and env, which encode the viral matrix, capsid, nucleocapsid, reverse transcriptase, integrase, and envelope proteins, respectively. Additionally, the virus carries accessory genes, such as rex and sor, that play a role in regulating viral gene expression and replication.

AKR MLV has been extensively studied as a model system for retrovirus biology and pathogenesis, and its study has contributed significantly to our understanding of the mechanisms of retroviral infection, replication, and disease.

Remission induction is a treatment approach in medicine, particularly in the field of oncology and hematology. It refers to the initial phase of therapy aimed at reducing or eliminating the signs and symptoms of active disease, such as cancer or autoimmune disorders. The primary goal of remission induction is to achieve a complete response (disappearance of all detectable signs of the disease) or a partial response (a decrease in the measurable extent of the disease). This phase of treatment is often intensive and may involve the use of multiple drugs or therapies, including chemotherapy, immunotherapy, or targeted therapy. After remission induction, patients may receive additional treatments to maintain the remission and prevent relapse, known as consolidation or maintenance therapy.

Interleukin-4 (IL-4) is a type of cytokine, which is a cell signaling molecule that mediates communication between cells in the immune system. Specifically, IL-4 is produced by activated T cells and mast cells, among other cells, and plays an important role in the differentiation and activation of immune cells called Th2 cells.

Th2 cells are involved in the immune response to parasites, as well as in allergic reactions. IL-4 also promotes the growth and survival of B cells, which produce antibodies, and helps to regulate the production of certain types of antibodies. In addition, IL-4 has anti-inflammatory effects and can help to downregulate the immune response in some contexts.

Defects in IL-4 signaling have been implicated in a number of diseases, including asthma, allergies, and certain types of cancer.

Chronic myeloid leukemia (CML) is a type of cancer that starts in certain blood-forming cells of the bone marrow. In chronic phase CML, the disease progresses slowly and may not cause any symptoms for a period of time. It is characterized by the overproduction of mature and immature white blood cells, called myeloid cells. These cells accumulate in the bone marrow and interfere with the production of normal blood cells, leading to anemia, fatigue, easy bruising, and increased risk of infection. The distinguishing genetic feature of CML is the presence of the Philadelphia chromosome, which is formed by a genetic translocation between chromosomes 9 and 22, resulting in the formation of the BCR-ABL fusion gene. This gene produces an abnormal protein that contributes to the development of leukemia. The chronic phase of CML can last for several years and is typically treated with targeted therapy such as tyrosine kinase inhibitors (TKIs) which target the BCR-ABL protein.

Coculture techniques refer to a type of experimental setup in which two or more different types of cells or organisms are grown and studied together in a shared culture medium. This method allows researchers to examine the interactions between different cell types or species under controlled conditions, and to study how these interactions may influence various biological processes such as growth, gene expression, metabolism, and signal transduction.

Coculture techniques can be used to investigate a wide range of biological phenomena, including the effects of host-microbe interactions on human health and disease, the impact of different cell types on tissue development and homeostasis, and the role of microbial communities in shaping ecosystems. These techniques can also be used to test the efficacy and safety of new drugs or therapies by examining their effects on cells grown in coculture with other relevant cell types.

There are several different ways to establish cocultures, depending on the specific research question and experimental goals. Some common methods include:

1. Mixed cultures: In this approach, two or more cell types are simply mixed together in a culture dish or flask and allowed to grow and interact freely.
2. Cell-layer cultures: Here, one cell type is grown on a porous membrane or other support structure, while the second cell type is grown on top of it, forming a layered coculture.
3. Conditioned media cultures: In this case, one cell type is grown to confluence and its culture medium is collected and then used to grow a second cell type. This allows the second cell type to be exposed to any factors secreted by the first cell type into the medium.
4. Microfluidic cocultures: These involve growing cells in microfabricated channels or chambers, which allow for precise control over the spatial arrangement and flow of nutrients, waste products, and signaling molecules between different cell types.

Overall, coculture techniques provide a powerful tool for studying complex biological systems and gaining insights into the mechanisms that underlie various physiological and pathological processes.

K562 cells are a type of human cancer cell that are commonly used in scientific research. They are derived from a patient with chronic myelogenous leukemia (CML), a type of cancer that affects the blood and bone marrow.

K562 cells are often used as a model system to study various biological processes, including cell signaling, gene expression, differentiation, and apoptosis (programmed cell death). They are also commonly used in drug discovery and development, as they can be used to test the effectiveness of potential new therapies against cancer.

K562 cells have several characteristics that make them useful for research purposes. They are easy to grow and maintain in culture, and they can be manipulated genetically to express or knock down specific genes. Additionally, K562 cells are capable of differentiating into various cell types, such as red blood cells and megakaryocytes, which allows researchers to study the mechanisms of cell differentiation.

It's important to note that while K562 cells are a valuable tool for research, they do not fully recapitulate the complexity of human CML or other cancers. Therefore, findings from studies using K562 cells should be validated in more complex model systems or in clinical trials before they can be translated into treatments for patients.

An antigen is a substance (usually a protein) that is recognized as foreign by the immune system and stimulates an immune response, leading to the production of antibodies or activation of T-cells. Antigens can be derived from various sources, including bacteria, viruses, fungi, parasites, and tumor cells. They can also come from non-living substances such as pollen, dust mites, or chemicals.

Antigens contain epitopes, which are specific regions on the antigen molecule that are recognized by the immune system. The immune system's response to an antigen depends on several factors, including the type of antigen, its size, and its location in the body.

In general, antigens can be classified into two main categories:

1. T-dependent antigens: These require the help of T-cells to stimulate an immune response. They are typically larger, more complex molecules that contain multiple epitopes capable of binding to both MHC class II molecules on antigen-presenting cells and T-cell receptors on CD4+ T-cells.
2. T-independent antigens: These do not require the help of T-cells to stimulate an immune response. They are usually smaller, simpler molecules that contain repetitive epitopes capable of cross-linking B-cell receptors and activating them directly.

Understanding antigens and their properties is crucial for developing vaccines, diagnostic tests, and immunotherapies.

Surface antigens are molecules found on the surface of cells that can be recognized by the immune system as being foreign or different from the host's own cells. Antigens are typically proteins or polysaccharides that are capable of stimulating an immune response, leading to the production of antibodies and activation of immune cells such as T-cells.

Surface antigens are important in the context of infectious diseases because they allow the immune system to identify and target infected cells for destruction. For example, viruses and bacteria often display surface antigens that are distinct from those found on host cells, allowing the immune system to recognize and attack them. In some cases, these surface antigens can also be used as targets for vaccines or other immunotherapies.

In addition to their role in infectious diseases, surface antigens are also important in the context of cancer. Tumor cells often display abnormal surface antigens that differ from those found on normal cells, allowing the immune system to potentially recognize and attack them. However, tumors can also develop mechanisms to evade the immune system, making it difficult to mount an effective response.

Overall, understanding the properties and behavior of surface antigens is crucial for developing effective immunotherapies and vaccines against infectious diseases and cancer.

Cell separation is a process used to separate and isolate specific cell types from a heterogeneous mixture of cells. This can be accomplished through various physical or biological methods, depending on the characteristics of the cells of interest. Some common techniques for cell separation include:

1. Density gradient centrifugation: In this method, a sample containing a mixture of cells is layered onto a density gradient medium and then centrifuged. The cells are separated based on their size, density, and sedimentation rate, with denser cells settling closer to the bottom of the tube and less dense cells remaining near the top.

2. Magnetic-activated cell sorting (MACS): This technique uses magnetic beads coated with antibodies that bind to specific cell surface markers. The labeled cells are then passed through a column placed in a magnetic field, which retains the magnetically labeled cells while allowing unlabeled cells to flow through.

3. Fluorescence-activated cell sorting (FACS): In this method, cells are stained with fluorochrome-conjugated antibodies that recognize specific cell surface or intracellular markers. The stained cells are then passed through a laser beam, which excites the fluorophores and allows for the detection and sorting of individual cells based on their fluorescence profile.

4. Filtration: This simple method relies on the physical size differences between cells to separate them. Cells can be passed through filters with pore sizes that allow smaller cells to pass through while retaining larger cells.

5. Enzymatic digestion: In some cases, cells can be separated by enzymatically dissociating tissues into single-cell suspensions and then using various separation techniques to isolate specific cell types.

These methods are widely used in research and clinical settings for applications such as isolating immune cells, stem cells, or tumor cells from biological samples.

Human T-lymphotropic virus 1 (HTLV-1) is a complex retrovirus that infects CD4+ T lymphocytes and can cause adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The virus is primarily transmitted through breastfeeding, sexual contact, or contaminated blood products. After infection, the virus integrates into the host's genome and can remain latent for years or even decades before leading to disease. HTLV-1 is endemic in certain regions of the world, including Japan, the Caribbean, Central and South America, and parts of Africa.

Lymphocyte depletion is a medical term that refers to the reduction in the number of lymphocytes (a type of white blood cell) in the body. Lymphocytes play a crucial role in the immune system, as they help to fight off infections and diseases.

Lymphocyte depletion can occur due to various reasons, including certain medical treatments such as chemotherapy or radiation therapy, immune disorders, viral infections, or bone marrow transplantation. This reduction in lymphocytes can make a person more susceptible to infections and diseases, as their immune system is weakened.

There are different types of lymphocytes, including T cells, B cells, and natural killer (NK) cells, and lymphocyte depletion can affect one or all of these types. In some cases, lymphocyte depletion may be temporary and resolve on its own or with treatment. However, in other cases, it may be more prolonged and require medical intervention to manage the associated risks and complications.

Precursor B-cell Acute Lymphoblastic Leukemia/Lymphoma (also known as Precursor B-cell ALL or Precursor B-cell Non-Hodgkin Lymphoma) is a type of cancer that affects the early stages of B-cell development. It is characterized by the uncontrolled proliferation of immature B-cells, also known as lymphoblasts, in the bone marrow, blood, and sometimes in other organs such as the lymph nodes. These malignant cells accumulate and interfere with the normal production of blood cells, leading to symptoms such as anemia, infection, and bleeding.

The distinction between Precursor B-cell ALL and Precursor B-cell Lymphoma is based on the site of involvement. If the majority of the cancerous cells are found in the bone marrow and/or blood, it is classified as a leukemia (ALL). However, if the malignant cells primarily involve the lymph nodes or other extramedullary sites, it is considered a lymphoma. Despite this distinction, both entities share similar biological features, treatment approaches, and prognoses.

It's important to note that medical definitions can vary slightly based on the source and context. For the most accurate information, consult authoritative resources such as medical textbooks or peer-reviewed articles.

Messenger RNA (mRNA) is a type of RNA (ribonucleic acid) that carries genetic information copied from DNA in the form of a series of three-base code "words," each of which specifies a particular amino acid. This information is used by the cell's machinery to construct proteins, a process known as translation. After being transcribed from DNA, mRNA travels out of the nucleus to the ribosomes in the cytoplasm where protein synthesis occurs. Once the protein has been synthesized, the mRNA may be degraded and recycled. Post-transcriptional modifications can also occur to mRNA, such as alternative splicing and addition of a 5' cap and a poly(A) tail, which can affect its stability, localization, and translation efficiency.

SCID mice is an acronym for Severe Combined Immunodeficiency mice. These are genetically modified mice that lack a functional immune system due to the mutation or knockout of several key genes required for immunity. This makes them ideal for studying the human immune system, infectious diseases, and cancer, as well as testing new therapies and treatments in a controlled environment without the risk of interference from the mouse's own immune system. SCID mice are often used in xenotransplantation studies, where human cells or tissues are transplanted into the mouse to study their behavior and interactions with the human immune system.

"Cells, cultured" is a medical term that refers to cells that have been removed from an organism and grown in controlled laboratory conditions outside of the body. This process is called cell culture and it allows scientists to study cells in a more controlled and accessible environment than they would have inside the body. Cultured cells can be derived from a variety of sources, including tissues, organs, or fluids from humans, animals, or cell lines that have been previously established in the laboratory.

Cell culture involves several steps, including isolation of the cells from the tissue, purification and characterization of the cells, and maintenance of the cells in appropriate growth conditions. The cells are typically grown in specialized media that contain nutrients, growth factors, and other components necessary for their survival and proliferation. Cultured cells can be used for a variety of purposes, including basic research, drug development and testing, and production of biological products such as vaccines and gene therapies.

It is important to note that cultured cells may behave differently than they do in the body, and results obtained from cell culture studies may not always translate directly to human physiology or disease. Therefore, it is essential to validate findings from cell culture experiments using additional models and ultimately in clinical trials involving human subjects.

Ovalbumin is the major protein found in egg white, making up about 54-60% of its total protein content. It is a glycoprotein with a molecular weight of around 45 kDa and has both hydrophilic and hydrophobic regions. Ovalbumin is a single polypeptide chain consisting of 385 amino acids, including four disulfide bridges that contribute to its structure.

Ovalbumin is often used in research as a model antigen for studying immune responses and allergies. In its native form, ovalbumin is not allergenic; however, when it is denatured or degraded into smaller peptides through cooking or digestion, it can become an allergen for some individuals.

In addition to being a food allergen, ovalbumin has been used in various medical and research applications, such as vaccine development, immunological studies, and protein structure-function analysis.

Inbred strains of mice are defined as lines of mice that have been brother-sister mated for at least 20 consecutive generations. This results in a high degree of homozygosity, where the mice of an inbred strain are genetically identical to one another, with the exception of spontaneous mutations.

Inbred strains of mice are widely used in biomedical research due to their genetic uniformity and stability, which makes them useful for studying the genetic basis of various traits, diseases, and biological processes. They also provide a consistent and reproducible experimental system, as compared to outbred or genetically heterogeneous populations.

Some commonly used inbred strains of mice include C57BL/6J, BALB/cByJ, DBA/2J, and 129SvEv. Each strain has its own unique genetic background and phenotypic characteristics, which can influence the results of experiments. Therefore, it is important to choose the appropriate inbred strain for a given research question.

Homologous transplantation is a type of transplant surgery where organs or tissues are transferred between two genetically non-identical individuals of the same species. The term "homologous" refers to the similarity in structure and function of the donated organ or tissue to the recipient's own organ or tissue.

For example, a heart transplant from one human to another is an example of homologous transplantation because both organs are hearts and perform the same function. Similarly, a liver transplant, kidney transplant, lung transplant, and other types of organ transplants between individuals of the same species are also considered homologous transplantations.

Homologous transplantation is in contrast to heterologous or xenogeneic transplantation, where organs or tissues are transferred from one species to another, such as a pig heart transplanted into a human. Homologous transplantation is more commonly performed than heterologous transplantation due to the increased risk of rejection and other complications associated with xenogeneic transplants.

A cell line that is derived from tumor cells and has been adapted to grow in culture. These cell lines are often used in research to study the characteristics of cancer cells, including their growth patterns, genetic changes, and responses to various treatments. They can be established from many different types of tumors, such as carcinomas, sarcomas, and leukemias. Once established, these cell lines can be grown and maintained indefinitely in the laboratory, allowing researchers to conduct experiments and studies that would not be feasible using primary tumor cells. It is important to note that tumor cell lines may not always accurately represent the behavior of the original tumor, as they can undergo genetic changes during their time in culture.

Natural Killer (NK) cells are a type of lymphocyte, which are large granular innate immune cells that play a crucial role in the host's defense against viral infections and malignant transformations. They do not require prior sensitization to target and destroy abnormal cells, such as virus-infected cells or tumor cells. NK cells recognize their targets through an array of germline-encoded activating and inhibitory receptors that detect the alterations in the cell surface molecules of potential targets. Upon activation, NK cells release cytotoxic granules containing perforins and granzymes to induce target cell apoptosis, and they also produce a variety of cytokines and chemokines to modulate immune responses. Overall, natural killer cells serve as a critical component of the innate immune system, providing rapid and effective responses against infected or malignant cells.

A neoplasm is a tumor or growth that is formed by an abnormal and excessive proliferation of cells, which can be benign or malignant. Neoplasm proteins are therefore any proteins that are expressed or produced in these neoplastic cells. These proteins can play various roles in the development, progression, and maintenance of neoplasms.

Some neoplasm proteins may contribute to the uncontrolled cell growth and division seen in cancer, such as oncogenic proteins that promote cell cycle progression or inhibit apoptosis (programmed cell death). Others may help the neoplastic cells evade the immune system, allowing them to proliferate undetected. Still others may be involved in angiogenesis, the formation of new blood vessels that supply the tumor with nutrients and oxygen.

Neoplasm proteins can also serve as biomarkers for cancer diagnosis, prognosis, or treatment response. For example, the presence or level of certain neoplasm proteins in biological samples such as blood or tissue may indicate the presence of a specific type of cancer, help predict the likelihood of cancer recurrence, or suggest whether a particular therapy will be effective.

Overall, understanding the roles and behaviors of neoplasm proteins can provide valuable insights into the biology of cancer and inform the development of new diagnostic and therapeutic strategies.

Th2 cells, or T helper 2 cells, are a type of CD4+ T cell that plays a key role in the immune response to parasites and allergens. They produce cytokines such as IL-4, IL-5, IL-13 which promote the activation and proliferation of eosinophils, mast cells, and B cells, leading to the production of antibodies such as IgE. Th2 cells also play a role in the pathogenesis of allergic diseases such as asthma, atopic dermatitis, and allergic rhinitis.

It's important to note that an imbalance in Th1/Th2 response can lead to immune dysregulation and disease states. For example, an overactive Th2 response can lead to allergic reactions while an underactive Th2 response can lead to decreased ability to fight off parasitic infections.

It's also worth noting that there are other subsets of CD4+ T cells such as Th1, Th17, Treg and others, each with their own specific functions and cytokine production profiles.

Bone marrow transplantation (BMT) is a medical procedure in which damaged or destroyed bone marrow is replaced with healthy bone marrow from a donor. Bone marrow is the spongy tissue inside bones that produces blood cells. The main types of BMT are autologous, allogeneic, and umbilical cord blood transplantation.

In autologous BMT, the patient's own bone marrow is used for the transplant. This type of BMT is often used in patients with lymphoma or multiple myeloma who have undergone high-dose chemotherapy or radiation therapy to destroy their cancerous bone marrow.

In allogeneic BMT, bone marrow from a genetically matched donor is used for the transplant. This type of BMT is often used in patients with leukemia, lymphoma, or other blood disorders who have failed other treatments.

Umbilical cord blood transplantation involves using stem cells from umbilical cord blood as a source of healthy bone marrow. This type of BMT is often used in children and adults who do not have a matched donor for allogeneic BMT.

The process of BMT typically involves several steps, including harvesting the bone marrow or stem cells from the donor, conditioning the patient's body to receive the new bone marrow or stem cells, transplanting the new bone marrow or stem cells into the patient's body, and monitoring the patient for signs of engraftment and complications.

BMT is a complex and potentially risky procedure that requires careful planning, preparation, and follow-up care. However, it can be a life-saving treatment for many patients with blood disorders or cancer.

A phenotype is the physical or biochemical expression of an organism's genes, or the observable traits and characteristics resulting from the interaction of its genetic constitution (genotype) with environmental factors. These characteristics can include appearance, development, behavior, and resistance to disease, among others. Phenotypes can vary widely, even among individuals with identical genotypes, due to differences in environmental influences, gene expression, and genetic interactions.

An epitope is a specific region on the surface of an antigen (a molecule that can trigger an immune response) that is recognized by an antibody, B-cell receptor, or T-cell receptor. It is also commonly referred to as an antigenic determinant. Epitopes are typically composed of linear amino acid sequences or conformational structures made up of discontinuous amino acids in the antigen. They play a crucial role in the immune system's ability to differentiate between self and non-self molecules, leading to the targeted destruction of foreign substances like viruses and bacteria. Understanding epitopes is essential for developing vaccines, diagnostic tests, and immunotherapies.

Secondary plasma cell leukemia (sPCL) results from the comparatively slow development of plasma cell/plasma cell precursor ... Plasma cell leukemia (PCL) is a plasma cell dyscrasia, i.e. a disease involving the malignant degeneration of a subtype of ... PCL may present as primary plasma cell leukemia, i.e. in patients without prior history of a plasma cell dyscrasia or as ... circulating plasma cells had a prognosis much worse than that for multiple myeloma and similar to that for plasma cell leukemia ...
In 2013 the Hairy Cell Leukemia Foundation was created when the Hairy Cell Leukemia Consortium and the Hairy Cell Leukemia ... "Integrated human T-cell leukemia virus II genome in CD8 + T cells from a patient with "atypical" hairy cell leukemia: evidence ... Hairy cell leukemia-variant (HCL-V), which shares some characteristics with B cell prolymphocytic leukemia (B-PLL), does not ... "LMB-2 to Treat Hairy Cell Leukemia" at ClinicalTrials.gov "Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia - Full Text ...
Types include: Large granular lymphocytic leukemia Adult T-cell leukemia/lymphoma T-cell prolymphocytic leukemia In practice, ... T-cell leukemia describes several different types of lymphoid leukemia which affect T cells. ... it can be hard to distinguish T-cell leukemia from T-cell lymphoma, and they are often grouped together. Durer, Ceren; Babiker ... "Adult T Cell Leukemia". StatPearls. StatPearls Publishing. PMID 32644394. Retrieved 22 November 2021. This article includes a ...
If the mast cells represent less than 10% of blood cells, the tumor is called "aleukemic" mast cell leukemia. Acute mast cell ... Mast cell leukemia is an extremely aggressive subtype of acute myeloid leukemia that usually occurs de novo but can, rarely, ... Measurement of histidine carboxylase in the marrow cells of patients with mast cell leukemia is a very sensitive marker of mast ... March 1999). "Expression of Bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia". Am. J. Hematol ...
Precursor B lymphoblastic leukemia 9940/3 - Hairy cell leukemia T-cell leukemia B-cell lymphoma "B-Cell Leukemia (Concept Id: ... A B-cell leukemia is any of several types of lymphoid leukemia which affect B cells. Types include (with ICD-O code):[citation ... Acute lymphoblastic leukemia, mature B-cell type 9833/3 - B-cell prolymphocytic leukemia 9835/3-9836/3 - ... B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma 9826/3 - ...
"Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia: Treatment Options , Cancer.Net". Cancer.Net. 2012-06-25. ... This type of leukemia is characterized by: More than 55% of circulating cells in peripheral blood (red blood cells, white blood ... A stem cell transplant is a procedure that uses highly specialized cells called hematopoietic stem cells to replace bone marrow ... cite book}}: ,journal= ignored (help) "B-cell Prolymphocytic Leukemia (B-PLL) , Chronic Lymphocytic Leukemia". www.knowcancer. ...
... is a disease with an aggressive, systemic proliferation of natural killer cells (NK cells) and a ... Currently Aggressive NK-cell leukemia, being a subtype of PTCL, is treated similarly to B-cell lymphomas. However, in recent ... The cell of origin is believed to be an NK cell. Blastoid NK cell lymphoma appears to be a different entity and shows no ... 2006;108:A401 Kwong YL, Chan AC, Liang RH (May 1997). "Natural killer cell lymphoma/leukemia: pathology and treatment". Hematol ...
Other names include T-cell chronic lymphocytic leukemia, "knobby" type of T-cell leukemia, and T-prolymphocytic leukemia/T-cell ... T-cell-prolymphocytic leukemia (T-PLL) is a mature T-cell leukemia with aggressive behavior and predilection for blood, bone ... Most patients with T-cell prolymphocytic leukemia require immediate treatment. T-cell prolymphocytic leukemia is difficult to ... "Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in ...
... is a form of lymphoid leukemia in which too many B-cell lymphoblasts (immature white ... as designated leukemia/lymphoma. ALL is the most prevalent childhood malignancy, with precursor B-cell ALL (B-ALL) accounting ... as capable to change phenotype of B cells toward precursor cells. In approximately two-thirds of pediatric B-ALL patients, ... blood cells) are found in the blood and bone marrow. It is the most common type of acute lymphoblastic leukemia (ALL). It is ...
... (PBX) refers to a family of transcription factors. Types include: PBX1 PBX2 PBX3 PBX4 Pre-B cell " ...
Distinct from adult T-cell leukemia where T-cell lymphotropic virus Type I causes malignant maturation of T-cells, T-ALL is a ... T-cell acute lymphoblastic leukemia (T-ALL) is a type of acute lymphoblastic leukemia with aggressive malignant neoplasm of the ... "T-Cell Acute Lymphoblastic Leukemia - My Cancer Genome". www.mycancergenome.org. Retrieved 2020-04-07. "Leukemia - Chronic T- ... "Pediatric T-Cell Acute Lymphoblastic Leukemia". atlasgeneticsoncology.org. Retrieved 2020-04-07. "Acute lymphoblastic leukemia ...
... (CMML) is a type of leukemia, which are cancers of the blood-forming cells of the bone marrow. ... Unlike MPNs, MDSs have a dysfunctional production of myeloid cells with a reduced number of mature cells. Many of the cells ... and chronic myelomonocytic leukemia (CMML) that was approved for use in the United States in July 2020. Hematopoietic stem cell ... as well as abnormal looking cells (dysplasia) in at least one type of blood cell. CMML shows characteristics of a ...
One week after the T cells were injected, the leukemia cells in his blood had disappeared.[needs update] The T cells were still ... "France - Lymphoproliferative Syndrome B-Cell Prolymphocytic Leukemia ,". icgc.org. Retrieved 2016-11-18. "Hairy Cell Leukemia ... hairy cell leukemia, high grade T cell lymphomas, acute myeloid leukemia, lung cancer, brain cancer, melanoma of the eye or ... but the neoplastic cells have a distinct morphology under the microscope (hairy cell leukemia cells have delicate, hair-like ...
... is divided into two types according to the kind of cell involved: B-cell prolymphocytic leukemia and T- ... It is usually classified as a kind of chronic lymphocytic leukemia. Hsi, Eric D. (1 January 2012). "12 - B-Cell Leukemias of ... v t e (Articles with short description, Short description is different from Wikidata, Lymphocytic leukemia, All stub articles, ...
... and cytoplasmic domain of LIF-R required for differentiation and growth arrest of myeloid leukemic cells". Leukemia & Lymphoma ... Leukemia inhibitory factor receptor has been shown to interact with glycoprotein 130. LIFR has also been identified as a breast ... "Entrez Gene: LIFR leukemia inhibitory factor receptor alpha". Timmermann A, Küster A, Kurth I, Heinrich PC, Müller-Newen G ( ... The leukemia inhibitory factor (LIF) is a polyfunctional cytokine that affects the differentiation, survival, and proliferation ...
T-cell LGL leukemia (T-LGLL) and natural-killer (NK)-cell LGL leukemia (NK-LGLL). As the name suggests, T-cell large granular ... The postulated cells of origin of T-LGLL leukemia are transformed CD8+ T-cell with clonal rearrangements of β chain T-cell ... The neoplastic cells of this disease display a mature T-cell immunophenotype, with the majority of cases showing a CD4-/CD8+ T- ... Alemtuzumab has been investigated for use in treatment of refractory T-cell large granular lymphocytic leukemia. Experimental ...
The basis of allogenic stem cell transplantation is on a graft versus leukemia effect whereby graft cells stimulate an immune ... delivering cell-killing substances to cancer cells, or starving cancer cells of hormones they need to grow. Other targeted ... occur when the leukemic cells can not be classified as either myeloid or lymphoid cells, or where both types of cells are ... Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal ...
May manifest basophil and mast cell granules by EM. Cytogenetically heterogeneous but frequently associated with Philadelphia ... Acute basophilic leukemia is a rare form of acute myeloid leukemia where blasts are accompanied by abnormal basophils in all ... Duchayne, E.; H. Rubier; A. Robert; N. Dastugue (1999). "Diagnosis of acute basophilic leukemia". Leukemia & Lymphoma. 32 (3-4 ... "Molecular pathogenesis of chromosome 16 inversion in the M4E0 subtypes of acute myeloid leukemia". Blood. 85 (9): 2289-2302. ...
Types of T-cell acute lymphoblastic leukemia include adult T-cell leukemia/lymphoma and (precursor) T-lymphoblastic leukemia/ ... T-lymphoblastic cells of acute leukemia in the bone marrow Acute erythroid leukemia, a rare form of acute myeloid leukemia ... Acute myeloid leukemia, a rare form of which is acute erythroid leukemia. Acute lymphoblastic leukemia including T-cell acute ... Yodoi, J; Takatsuki, K; Masuda, T (1974). "Letter: Two cases of T-cell chronic lymphocytic leukemia in Japan". New England ...
Stem cell transplant is a process in which the blood-forming cells that are abnormal (like leukemia cells) or that were ... Stem cell transplants can use the cells from one's self, called an autologous stem cell transplant or they can use cells from ... The white blood cells overproduce, crowding the other blood cells in the bone marrow. Another type of acute leukemia is acute ... When a child has leukemia, the cells do not respond to the signals telling them when to stop and when to produce cells. The ...
... only in their leukemia cells) Another 35% of patients with a mutation in a gene called PTPN11 (again, only in their leukemia ... by harboring dormant JMML cells that are not eradicated by radiation therapy or chemotherapy for the active leukemia cells, ... Graft versus leukemia: Graft versus leukemia has been shown many times to play a critical role in curing JMML, and it is ... Juvenile myelomonocytic leukemia (JMML) is a rare form of chronic leukemia (cancer of the blood) that affects children, ...
Large granular lymphocytic leukemia may involve either T-cells or NK cells; like hairy cell leukemia, which involves solely B ... Despite its overall rarity, it is the most common type of mature T cell leukemia; nearly all other leukemias involve B cells. ... These blood cells are not fully developed and are called blasts or leukemia cells. Symptoms may include bleeding and bruising, ... Hairy cell leukemia (HCL) is sometimes considered a subset of chronic lymphocytic leukemia, but does not fit neatly into this ...
These tumors are malignancies of germ cells, i.e. primitive cells that give rise to sperm and ovum cells. In adult-AMKL, ... Acute megakaryoblastic leukemia (AMKL) is life-threatening leukemia in which malignant megakaryoblasts proliferate abnormally ... Gassmann W, Löffler H (1995). "Acute megakaryoblastic leukemia". Leukemia & Lymphoma. 18 Suppl 1: 69-73. doi:10.3109/ ... mediastinal germ cell tumors that are associated with adult-AMKL are not seminomas (i.e. do not originate from the sperm cell ...
... of the cells in the blood and bone marrow are blast cells (immature blood cells). In the accelerated phase, these leukemia ... Accelerated phase chronic myelogenous leukemia is a phase of chronic myelogenous leukemia in which the disease is progressing. ... "Chronic myelogenous leukemia (CML)". Shah, NP (Mar 2008). "Advanced CML: therapeutic options for patients in accelerated and ... Accelerated phase chronic myelogenous leukemia entry in the public domain NCI Cancer Dictionary v t e (CS1: long volume value, ...
Entry into host cell: Then GaLV particles use these cell-surface proteins on the cell membrane, as specific receptors to enter ... lymphoblastic leukemia, osteoporosis and granulocytic leukemia. In cases of granulocytic leukemia, increased granulocytes in ... and Snyder et al., 1973) GALV‐X: detected in cell culture from a human T-cell line infected with HIV-1 in Louvain, Belgium and ... Gallo et al., 1978) GaLV-Mar: detected in cell culture (in vitro) derived from marmoset cells. Simian sarcoma (SSV): a ...
One can use the experience with BLV for understanding HTLV-I induced diseases like ATL (adult T-cell leukemia) and HAM/TSP ( ... Only some animals later develop a B-cell leukemia called enzootic bovine leukosis. Under natural conditions the disease is ... "Bovine leukemia virus". NCBI Taxonomy Browser. 11901. "Bovine Leukemia Virus (BLV)". APHIS (Animal and Plant Health Inspection ... Bovine leukemia virus (BLV) is a retrovirus which causes enzootic bovine leukosis in cattle. It is closely related to the human ...
... may refer to: Chronic myelogenous leukemia Chronic lymphocytic leukemia, including Hairy cell leukemia ... Chronic leukemia is an increase of abnormal white blood cells. It differs from acute leukemia, and is categorized as ... chronic neutrophilic leukemia , and chronic eosinophilic leukemia. This article includes a list of related items that share the ...
Chronic myelogenous leukemia: A cancer of the white blood cells. Acute megakaryoblastic leukemia: A life-threatening leukemia ... Myeloid leukemia is a type of leukemia affecting myeloid tissue. Types include: Acute myeloid leukemia: A cancer of the myeloid ... Blastic plasmacytoid dendritic cell neoplasm: A rare hematologic malignancy which is a malignancy of plasmacytoid dendritic ... line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and ...
... stable productive cells, non-productive cells and cells which produced defective virus particles which are not infective. ... Rosenberg N, Baltimore D, Scher CD (1975). "In vitro transformation of lymphoid cells by Abelson murine leukemia virus". Proc. ... Shields A, Rosenberg N, Baltimore D (1979). "Virus production by Abelson murine leukemia virus-transformed lymphoid cells". J. ... It can infect B-cells which was shown by the fact that some tumor cells can be seen to have immunoglobulins (Ig) on their ...
Acute erythroid leukemias can be classified as follows: 50% or more of all nucleated bone marrow cells are erythroblasts, ... Acute erythrocyte leukemia is a rare form of acute myeloid leukemia (less than 5% of AML cases) where the myeloproliferation is ... Acute erythroid leukemia is rare, accounting for only 3-5% of all acute myeloid leukemia cases. One study estimated an ... Despite this lack of myeloblasts, these cases should be considered acute leukemias. In a WHO proposal the blastic leukemias ...
Secondary plasma cell leukemia (sPCL) results from the comparatively slow development of plasma cell/plasma cell precursor ... Plasma cell leukemia (PCL) is a plasma cell dyscrasia, i.e. a disease involving the malignant degeneration of a subtype of ... PCL may present as primary plasma cell leukemia, i.e. in patients without prior history of a plasma cell dyscrasia or as ... circulating plasma cells had a prognosis much worse than that for multiple myeloma and similar to that for plasma cell leukemia ...
Treatment protocols for hairy cell leukemia (HCL) are provided below, including those for initial treatment, resistant disease ... Variant hairy cell leukemia. Variant hairy cell leukemia is resistant to the standard treatments, which include the use of ... How is relapsed hairy cell leukemia treated?. What is the role of moxetumomab pasudotox in the treatment of hairy cell leukemia ... encoded search term (Hairy Cell Leukemia Treatment Protocols) and Hairy Cell Leukemia Treatment Protocols What to Read Next on ...
These compounds exhibited synergy with several anti-leukemia agents in AML, acute lymphoblastic leukemia (ALL), or chronic ... and/or apoptotic cell death in AML cell lines and refractory/relapsed AML primary samples. ... Compounds derived from PS127 significantly upregulated production of reactive oxygen species (ROS) in AML cells and triggered ... We identified six mitochondria-affecting compounds (PS compounds) that exhibit selective cytotoxicity against AML cells in ...
The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against blood cancer. The LLS mission: Cure leukemia, ... The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest ... This fact sheet provides information about the diagnosis and management of mantle cell lymphoma. ...
The study involved 30 people with hairy cell leukemia that had come back after or had not responded to previous treatment. ... Hairy cell leukemia occurs when abnormal, hairy-looking white blood cells build up in the bone marrow, spleen, and bloodstream ... Similarly, treating hairy cell leukemia with rituximab-a drug that binds to a protein called CD20 on white blood cells-doesnt ... Hairy cell leukemia is so named because the cancerous blood cells (purple) appear "hairy" when viewed with a microscope. ...
It has important genetic variances that differentiate it from classic hairy cell leukemia. ... HCL-V is a distinct form of chronic lymphocytic leukemia. ... of leukemia diagnoses are HCL.. Hairy cell leukemia-variant ( ... Rare types of leukemia include hairy cell leukemia, large granular lymphocytic (LGL) leukemia, and mast cell leukemia. ... such as B cells (and further into plasma cells), T cells, and natural killer cells. Leukemias affecting these cells are called ...
Preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer ... cells in some chronic myeloid leukemia patients taking the drug Imatinib mesylate (Gleevec). ... Potential Seen for Tailoring Treatment for Acute Myeloid Leukemia. Dec. 7, 2018 Rapid screening of leukemia cells for drug ... made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia ...
Diagnosis and current treatment options for hairy cell leukemia (HCL). *Clinical trials and emerging therapies for HCL ... The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against blood cancer. The LLS mission: Cure leukemia, ... The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest ... Support for this program provided by AstraZeneca and The Leukemia & Lymphoma Society. ...
... patients with hairy cell leukemia who have not responded or relapsed after initial chemotherapy will be randomly assigned to ... These abnormal cells appear "hairy" when viewed under a microscope and give the disease its name. Hairy cell leukemia is ... CD20-positive cells). Moreover, rituximab has been used successfully to treat some patients with hairy cell leukemia who have ... Hairy cell leukemia is an uncommon cancer of the blood in which the body produces a large number of abnormal B lymphocytes (a ...
... provided durable remission with long-term persistence in pediatric and young adult patients with relapsed or refractory B-cell ... In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel ... Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia N Engl J Med. 2018 Feb 1;378(5):439-448. doi: ... Background: In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel ...
Successful treatment of therapy-resistant chronic leukemia using allogeneic stem cell transplantation ... 2023 from www.disabled-world.com/health/cancer/leukemia/Treatment-of-Therapy-resistant-Chronic-Leukemia-Using-Stem-Cells.php. ... www.disabled-world.com/health/cancer/leukemia/Treatment-of-Therapy-resistant-Chronic-Leukemia-Using-Stem-Cells.php",Treatment ... "It is crucial to control the transplanted donor immune cells so that the effect is strong enough to eliminate the leukemia ...
... to identify the kind of cell that leads to a given case of leukemia, a valuable key to cancer prognosis and outcome. ... Every cancer starts with a single cell, and Jackson Laboratory researchers have found a precise and reliable way -- whole- ... Acute Myeloid Leukemia, B Cell, Biomarker, Bone, Bone Marrow, Cancer, Cancer Biomarker, Cell, Cell Division, Cell Line, Cell ... Leukemia, Macrophage, Mouse Model, Myeloid Leukemia, Oncogene, Progenitor Cells, RNA, Stem Cells, T-Cell, Tumor, Wound, X ...
... a costimulatory receptor in T cells [4-1BB]) and CD3-zeta (a signal-transduction component of the T-cell antigen receptor) ... We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the B-cell antigen CD19, coupled ... A specific immune response was detected in the bone marrow, accompanied by loss of normal B cells and leukemia cells that ... Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N Engl J Med. 2011 Aug 25;365(8):725-33. doi: 10.1056/ ...
Mark Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor ... Mark Computational Single-Cell Genomics Methods for Cell State Estimation and their Application to Hematopoietic Systems ... Mark Schlafen2 is a regulator of quiescence in adult murine hematopoietic stem cells Warsi, Sarah LU ; Dahl, Maria LU ; Smith, ... Mark Scarf enables a highly memory-efficient analysis of large-scale single-cell genomics data Dhapola, Parashar LU ; Rodhe, ...
T Cell Immunotherapy for Childhood Leukemia. Shannon Maude, M.D., Ph.D. Rally for Ryan Fund St. Baldricks Scholar. Fellowship ... Grand Rounds: T Cell Immunotherapy for Childhood Leukemia. Date. : December 6, 2017 ...
LncRNA NALT interaction with NOTCH1 promoted cell proliferation in pediatric T cell acute lymphoblastic leukemia. Wang Y, et al ... NALT1 NOTCH1 associated lncRNA in T cell acute lymphoblastic leukemia 1 [Homo sa... NALT1 NOTCH1 associated lncRNA in T cell ... Title: LncRNA NALT interaction with NOTCH1 promoted cell proliferation in pediatric T cell acute lymphoblastic leukemia. ... NOTCH1 associated lncRNA in T cell acute lymphoblastic leukemia 1provided by HGNC. Primary source. HGNC:HGNC:51192 See related ...
Since SLAMF receptors play a role in NK cell biology, we reasoned that these receptors may impact NK cell-mediated CLL immunity ... Overexpression of SLAMF1 or SLAMF7 in IGHV mutated CLL cell models resulted in reduced proliferation and impaired responses to ... Indeed, our experiments showed significantly decreased degranulation capacity of primary NK cells from CLL patients expressing ... we investigated the impact of SLAMF1 and SLAMF7 on the B cell receptor (BCR) signaling axis. ...
Learn more in this Cancer.Net Guide to B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia. ... Leukemia is a cancer of the blood cells which begins when normal blood cells change and grow uncontrollably. ... Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia , *Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell ... Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia up Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell ...
... can destroy leukemia cells either alone or in combination with other cancer treatments. The scientific community has long- ... established that cannabinoids may show potential in cancer treatment, with certain varieties known to promote cell death, curb ... against leukemia cells. The researcher found that the compounds spurred significant declines in cancer cell viability and ... The study revealed that the cannabiniod varieties cannabidiol and tetrahydrocannabinol (THC) eliminated leukemia cells when ...
Instead of targeting a molecule called CD19 on the surface of the cancer cells, the new therapy targets a molecule called CD22. ... CAR T-cell therapy relies on a patients own T cells - a type of immune cell that can be a powerful killing machine. ... Researchers genetically modify the T cells to recognize specific molecules on the cancer cells surfaces and kill the cells. ... Stanford Medicine News 2017 11 Possible new cell therapy for leukemia Story ...
... has successfully manufactured the UAEs first CAR-T cells to treat an 11-year-old boy with leukemia. Engineered CAR-T cells ... Abu Dhabi manufactures UAEs first CAR-T Cell to treat 11-year old leukemia patient. ... Physicians withdrew the cells from the patient and genetically modified his immune cells in the laboratory to fight the cancer ... The child, Murad, was diagnosed with leukemia more than five years ago and went into remission, but unfortunately, the leukemia ...
Fraunhofer Institute for Cell Therapy and Immunology IZI - Doctoral scholarship for leukemia cell research ... supports the development of an organ-on-a-chip model for the cultivation and investigation of leukemia cells. ... Preclinical and clinical development of a novel CAR-T cell therapy for the treatment of multiple myeloma and clear cell renal ... www.izi.fraunhofer.de/en/press/press-releases/doctoral-scholarship-for-leukemia-cell-research.html ...
... leukemia_cells_in_mice_using_natural_killer_nk_cells_from_umbilical_cord_blood ... NK cells operate differently from T cells, leaving normal cells alone while targeting and killing the cancerous cells. ... these NK cells reduced the circulating human acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML) cells by 60 ... "These NK cells demonstrate significant cytotoxic activity against human AML and ALL cell lines and patient leukemia blasts. ...
Variant Human T-cell Lymphotropic Virus Type 1c and Adult T-cell Leukemia, Australia Lloyd Einsiedel1. , Olivier Cassar1, Peter ... C) Peripheral blood cells smear from adult T-lymphocytic leukemia patient 1 (Aus-NR). Tumor cells exhibiting multilobulated ... Variant Human T-cell Lymphotropic Virus Type 1c and Adult T-cell Leukemia, Australia. ... CD3 (A) and CD4 (B) cells immunostained with diaminobenzidine and horseradish peroxidase in lymph node biopsy sample from ...
Treatment protocols for hairy cell leukemia (HCL) are provided below, including those for initial treatment, resistant disease ... Variant hairy cell leukemia. Variant hairy cell leukemia is resistant to the standard treatments, which include the use of ... How is relapsed hairy cell leukemia treated?. What is the role of moxetumomab pasudotox in the treatment of hairy cell leukemia ... encoded search term (Hairy Cell Leukemia Treatment Protocols) and Hairy Cell Leukemia Treatment Protocols What to Read Next on ...
B-cell prolymphocytic leukemia. No criteria for the classification of B-cell prolymphocytic leukemia has emerged. [1] ... American Roentgen Ray Society Images of B-cell prolymphocytic leukemia classification All Images. X-rays. Echo & Ultrasound. CT ... There is classification sysytem for B-cell prolymphocytic leukemia. ... Retrieved from "https://www.wikidoc.org/index.php?title=B-cell_prolymphocytic_leukemia_classification&oldid=1561999" ...
MSK investigators have used a lab tool originally developed to study fly nerve cells to uncover new findings about acute ... The cells they used were blood stem cells from mice and leukemia stem cells from mice and humans. ... "We knew that leukemia cells seemed to be more addicted to Musashi-2 for their growth than normal cells," Dr. Kharas says. "Now ... Kharass lab learned that Musashi-2 behaves differently in leukemia cells than it does in regular blood stem cells. " ...
The study published in Cell Reports reveals that these precursor cells ensure that the thymus keeps generating T cells, even in ... Team of researchers led by IGC PI Vera Martins identified the cells that can sustain immune cell differentiation in the thymus ... But this entails serious consequences: the appearance of abnormal cells, which accumulate errors and trigger leukaemia ...
... off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with potential implications for the future of gene ... Base-Edited T Cells Could Minimize Immunotherapy Complications in Leukemia, Study Suggests. November 18, 2023. Aislinn Antrim ... Use of base editing to create universal CAR T cells for advanced leukemia. N Engl J Med. 2023;389(10):944-953. doi:10.1056/ ... The use of base editing to generate universal, off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with ...
Developing engineered autologous leukemia vaccines to target residual leukemic stem cells. Return to Grants ... Our engineered vaccine is designed to stimulate the patients own immune system to generate leukemia specific immune cells that ... We propose a powerful strategy for converting patients leukemia cells into effective vaccines that stimulate anti-leukemic ... the vast majority of these individuals relapse within a year due to the persistence of residual AML and leukemia stem cells. ...
  • These compounds exhibited synergy with several anti-leukemia agents in AML, acute lymphoblastic leukemia (ALL), or chronic myelogenous leukemia (CML). (nature.com)
  • HCL-V affects B cells, so it's classified as a chronic lymphocytic leukemia (CLL). (healthline.com)
  • It's a chronic form of leukemia, meaning it's typically a more slowly developing form of the disease. (healthline.com)
  • Yet another drug, called bendamustine , has been shown to be effective against other cancers involving B lymphocytes, such as some B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. (cancer.gov)
  • Preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia patients taking the drug Imatinib mesylate (Gleevec). (sciencedaily.com)
  • Successful treatment of therapy-resistant chronic leukemia using allogeneic stem cell transplantation. (disabled-world.com)
  • The transplantation of stem cells from a healthy donor (allogeneic) offers the chance of cure for patients with an aggressive form of chronic lymphocytic leukemia (CLL), irrespective of genetic prognostic factors and the prior course of the disease. (disabled-world.com)
  • Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the GCLLSG CLL3X Trial. (disabled-world.com)
  • A low dose (approximately 1.5×10(5) cells per kilogram of body weight) of autologous chimeric antigen receptor-modified T cells reinfused into a patient with refractory chronic lymphocytic leukemia (CLL) expanded to a level that was more than 1000 times as high as the initial engraftment level in vivo, with delayed development of the tumor lysis syndrome and with complete remission. (nih.gov)
  • We identified a subset of Chronic Lymphocytic Leukemia (CLL) patients with high Signaling Lymphocytic Activation Molecule Family (SLAMF) receptor-related signaling that showed an indolent clinical course. (nature.com)
  • B cell receptor (BCR) signaling plays a critical role in driving proliferation and survival of the malignant clone in chronic lymphocytic leukemia (CLL), supported by the clinical activity of inhibitors targeted toward BCR-associated kinases [ 1 ]. (nature.com)
  • PLL and HCL are types of chronic B-cell leukemia. (cancer.net)
  • Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in the western world. (europa.eu)
  • B cell chronic lymphocytic leukemia (CLL) is the most frequent leukemia in adults. (europa.eu)
  • According to a research article published in September 2021, chronic lymphocytic leukemia (CLL) patients are more susceptible to serious infections due to the immunodeficiency caused by the disease and its therapy, and COVID-19 continued to have a high admission rate even among consecutive and young early-stage CLL patients. (mordorintelligence.com)
  • Furthermore, according to an article published in October 2021, it has been observed that chronic lymphocytic leukemia (CLL) is one of the most frequent kinds of leukemia, with an age-adjusted incidence of 4.9 per 100,000 people per year. (mordorintelligence.com)
  • In previous research, the authors demonstrated that the methanol extract of Artemisia vulgaris (AVM) has the ability to inhibit chronic myeloid leukemia (CML) cell proliferation. (spandidos-publications.com)
  • Chronic myeloid leukemia (CML) is a malignancy of the blood and bone marrow that affects children and adults. (spandidos-publications.com)
  • His past medical history was significant for subclinical B-cell chronic lymphocytic leukemia (CLL), which had never been treated. (cdlib.org)
  • Chronic lymphocytic leukemia (CLL) is the most common adult leukemia with an incidence of 3-5 per 100,000 [ 1 ]. (cdlib.org)
  • To identify regulators of primitive chronic myeloid leukemia (CML) cells, we performed a high-content cytokine screen using primary CD34 + CD38 low chronic phase CML cells. (haematologica.org)
  • Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by an acquired 9;22-chromosomal translocation in a hematopoietic stem cell (HSC) resulting in the expression of the BCR-ABL1 fusion protein. (haematologica.org)
  • Vibecotamab(XmAb-14045) is under development for the treatment of hematologic malignancies such as relapsed/refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, blastic plasmacytoid dendritic cell neoplasm, myelodysplastic syndrome and chronic myeloid leukemia. (pharmaceutical-technology.com)
  • This monograph only gives information about ofatumumab injection (Arzerra) for treatment of chronic lymphocytic leukemia. (medlineplus.gov)
  • See Chronic Leukemias: 4 Cancers to Differentiate , a Critical Images slideshow, to help detect chronic leukemias and determine the specific type present. (medscape.com)
  • These reflect the differentiation between the immature B-cell of chronic lymphocytic leukemia and the plasma cell of multiple myeloma. (medscape.com)
  • Define leukemic stem cell (LSCs) and identify therapy-insensitive cells in chronic myeloid leukemia (CML). (lu.se)
  • These cells can turn into either a myeloid stem cell or a lymphoid stem cell. (healthline.com)
  • Lymphoid stem cells can mature into other types of white stem cells, such as B cells (and further into plasma cells), T cells, and natural killer cells. (healthline.com)
  • Lymphoid cells. (cancer.net)
  • White blood cells mostly found in the lymphoid tissues, such as the spleen, lymph nodes, and tonsils. (cancer.net)
  • This hypothesis has not been confirmed by other reports, although a French study that evaluated occupational exposure to pesticides and lymphoid neoplasms among men appears to support the hypothesis that occupational pesticide exposures may not only be involved in hairy cell leukemia, Hodgkin lymphoma, and multiple myeloma, but also may play a role in non-Hodgkin lymphoma. (medscape.com)
  • in this group of patients and the role of IFN- , a commonly mately 2-4% of lymphoid leukemias. (bvsalud.org)
  • For births 1989-2016, paternal exposure from offspring birth to cancer diagnosis was negatively associated with acute lymphoid leukemia ( OR = 0.58, 95% CI 0.33-1.00). (cdc.gov)
  • These results bear out indications in human data that the stage of a progenitor cell when it becomes transformed to leukemia has an impact on its clinical progression, with earlier-stage cell of origin cancers being more aggressive. (news-medical.net)
  • With the support of UAE's leadership and the Department of Health - Abu Dhabi, we aim to revolutionize perceptions of cancer treatment by pushing the limits of what can be achieved through cell therapy where genetically modified immune cells are used to precisely target tumors in individuals with specific blood cancers. (zawya.com)
  • For these patients, cellular immunotherapy could help achieve deep leukemic clearance, although chimeric antigen receptor (CAR) T-cell strategies against T-cell cancers have been difficult. (ajmc.com)
  • We also hope that our approach could improve the manufacturing of CAR-T cells moving forward, which could have implications for the treatment of other cancers. (vchri.ca)
  • In a small study, the combination of two targeted therapies led to long-lasting remission s for the majority of patients with hairy cell leukemia that had come back after previous treatments. (cancer.gov)
  • A patient was considered to have a complete remission if they had no hairy leukemia cells visible in their bone marrow and blood (using a microscope), normal blood cell counts , and no swelling in their spleen at the end of the treatment. (cancer.gov)
  • For many types of leukemia, including hairy cell, "it makes the complete remission [last] a lot longer if you can eliminate minimal residual disease," Dr. Kreitman explained. (cancer.gov)
  • In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). (nih.gov)
  • In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients with relapsed or refractory B-cell ALL, with transient high-grade toxic effects. (nih.gov)
  • A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according by researchers at the Stanford University School of Medicine and the National Cancer Institute . (stanford.edu)
  • At the lowest dose level, one in six patients achieved complete remission after treatment with the anti-CD22 CAR T cells. (stanford.edu)
  • The child, Murad, was diagnosed with leukemia more than five years ago and went into remission, but unfortunately, the leukemia returned approximately six months ago. (zawya.com)
  • On day 27, the patient's bone marrow was hypocellular and in morphologic remission with undetectable minimal residual disease and she was discharged 52 days after stem-cell transplantation. (ajmc.com)
  • However, it impacts all cells in the body, and only achieves long-term cancer remission for between 30-40 per cent of adult patients . (vchri.ca)
  • Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. (medscape.com)
  • Your bone marrow contains blood stem cells. (healthline.com)
  • Myeloid stem cells mature into red blood cells, platelets, or one of many types of white blood cell called granulocytes. (healthline.com)
  • the Division of Stem Cell Transplantation and Immunology, Hospital for Children and Adolescents, University Hospital Frankfurt, Frankfurt, Germany (P.B. (nih.gov)
  • the Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, and the Cancer Research Institute Ghent (CRIG), Ghent, Belgium (B.D.M. (nih.gov)
  • the Stem Cell Transplantation Unit, St. Anna Children's Hospital, Vienna (C.P. (nih.gov)
  • The German CLL Study Group proved this in a multi-centric clinical phase II study led by Professor Dr. Peter Dreger, senior consultant and head of the division of stem cell transplantation at the Department of Internal Medicine V at Heidelberg University Hospital. (disabled-world.com)
  • Our study is the largest so far for this patient population and proved that allogeneic stem cell transplantation is a promising therapy option for high-risk CLL and has the potential to cure for this otherwise incurable kind of leukemia," says Professor Dreger, head of the study. (disabled-world.com)
  • Allogeneic stem cell transplantation is a very stressful and risky form of therapy, which could previously not be carried out on the generally older patients affected by CLL. (disabled-world.com)
  • They began with five distinct, normal cell types found in the bone marrow in both mice and humans: long-term hematopoietic stem cells (HSCs), short-term HSCs, multipotent progenitors, common myeloid progenitors and granulocyte macrophage progenitors. (news-medical.net)
  • The AML that developed from these different cells of origin had different penetrance and aggressiveness when engrafted in mice, with the stem cell-derived lines being the most aggressive and the committed progenitor lines the least. (news-medical.net)
  • Together they identified open chromatin signatures and gene expression patterns in AML samples that may allow stem cell-derived AML to be distinguished from progenitor cell of origin AML. (news-medical.net)
  • ABU DHABI: Abu Dhabi Stem Cells Center (ADSCC), a PureHealth subsidiary and the largest healthcare platform in the Middle East, has successfully manufactured the UAE's first CAR-T cells to treat an 11-year-old boy with leukemia. (zawya.com)
  • The treatment took five weeks, during which Murad was admitted at ADSCC, the only accredited Centre of Excellence in Hematopoietic Stem Cell Transplantation in Abu Dhabi. (zawya.com)
  • However, Zweidler-McKay and co-senior investigator Elizabeth Shpall, M.D., professor in M. D. Anderson's Department of Stem Cell Transplantation and Cellular Therapy, have found a novel process to increase NK cells in cord blood more than 30-fold, generating more than 150 million NK cells from one cord blood unit while maintaining their activation to find and kill acute leukemia cells. (biologynews.net)
  • Graft-versus-host disease is a common side effect of patients receiving stem cell transplants, which results when the T cells in the transplanted blood react against the patient's own cells. (biologynews.net)
  • However, in 1988, researchers found cord blood to be another source for stem cell transplantation. (biologynews.net)
  • These immature stem cells were easier to match to patients, especially those from non-Caucasian ethnicities, and could be stored for use as needed. (biologynews.net)
  • Zweidler-McKay also predicts this type of transplant could be used for adults who have already had a transplant or for those adult and pediatric patients who aren't candidates for other stem cell transplants due to blood counts or illness. (biologynews.net)
  • However, the vast majority of these individuals relapse within a year due to the persistence of residual AML and leukemia stem cells. (ca.gov)
  • Our engineered vaccine is designed to stimulate the patient's own immune system to generate leukemia specific immune cells that can recognize, and kill residual leukemia stem cells. (ca.gov)
  • Most children with T-cell acute lymphoblastic leukemia (ALL) can be treated with standard chemotherapy regimens, but patients with induction failure or elevated minimal residual disease after consolidation generally receive allogeneic stem-cell transplantation. (ajmc.com)
  • Finally, patient 3 is a 15-year-old boy who first presented with mixed-phenotype acute leukemia in 2016 and underwent a first allogeneic stem cell transplantation from a matched unrelated donor. (ajmc.com)
  • Additionally, 53.2% of patients were refractory to their last prior line of therapy, and 38.3% had underwent allogeneic stem cell transplant. (cancernetwork.com)
  • Using stem cells from an umbilical cord from Japan, her best prospect of defeating the illness is now a new type of stem cell therapy. (cellmedicine.com)
  • This will basically wipe out her own immune system in readiness for the new stem cells to be transplanted into her. (cellmedicine.com)
  • ALL occurs when cancer grows inside of stem cells found in the body's bone marrow. (vchri.ca)
  • Stem cells have the ability to develop into components of blood: white and red blood cells, along with platelets. (vchri.ca)
  • Aberrantly expressed cytokines in the bone marrow (BM) niche are increasingly recognized as critical mediators of survival and expansion of leukemic stem cells. (haematologica.org)
  • A pro-inflammatory environment is thought to provide a selective advantage for the leukemic stem cells (LSC). (haematologica.org)
  • OBJECTIVES: I. Determine whether mixed or full donor chimerism can be safely established in older patients with acute myeloid leukemia (AML) treated with nonmyeloablative conditioning comprised of low dose total body irradiation, followed by allogeneic peripheral blood stem cell transplantation, followed by unrelated donor lymphocyte infusion (DLI). (knowcancer.com)
  • OUTLINE: Conditioning: Patients undergo low dose total body irradiation followed by infusion of allogeneic peripheral blood stem cells (PBSC) on day 0. (knowcancer.com)
  • The production of blood cells, hematopoiesis, is maintained by a small number of hematopoietic stem cells (HSCs) that have the capacity to differentiate into all hematopoietic lineages, and at the same time self-renew to maintain the HSC pool. (lu.se)
  • Similarly to normal hematopoiesis, leukemias are organized in cellular hierarchies where leukemic stem cells (LSCs) drive the tumor growth. (lu.se)
  • LSCs have stem cell characteristics such as self-renewal capacity, quiescence and drug resistance, causing metastasis and relapse. (lu.se)
  • The objective of our research is to molecularly dissect known stem cell populations in order to discriminate between normal and malignant stem cells. (lu.se)
  • Delineate the heterogeneity of human hematopietic stem cell (HSC) populations at different ontogenetic stages and identify novel markers for improved HSC isolation. (lu.se)
  • Signaling pathways governing the behaviors of leukemia stem cells. (bvsalud.org)
  • Recent studies showed that leukemia stem cells (LSCs) play essential roles in the pathogenesis of leukemia by targeting several signaling pathways, including Notch, Wnt, Hedgehog , and STAT3. (bvsalud.org)
  • Hematopoietic stem cell transplantation has become a major treatment option for patients with hematopoietic malignancies and immune deficiencies. (cdc.gov)
  • To the best of our knowledge, only the transmission of malarial parasites has been reported during stem cell transplantation. (cdc.gov)
  • Here, we report transmission of dengue virus to a peripheral blood stem cell recipient by a donor who had recently traveled to an area to which the virus is endemic. (cdc.gov)
  • Because of the patient's risk status, the physicians intended to perform allogeneic stem cell transplantation after induction and consolidation chemotherapy, which was scheduled to end in January 2013, and a conditioning chemotherapy regimen, which was planned to be given in March. (cdc.gov)
  • The stem cell mobilization result was poor. (cdc.gov)
  • Acute myeloid leukemia (AML) is a heterogeneous group of aggressive hematological malignancies commonly associated with treatment resistance, high risk of relapse, and mitochondrial dysregulation. (nature.com)
  • Leukemias affecting these cells are called myeloid leukemias. (healthline.com)
  • Her lab worked with a mouse model of acute myeloid leukemia (AML) driven by expression of MLL-AF9, a fusion oncogene formed by a chromosome translocation between human chromosomes 9 and 11. (news-medical.net)
  • Myeloid cells. (cancer.net)
  • The technique has allowed them to uncover new clues about acute myeloid leukemia. (mskcc.org)
  • She is suffering with acute myeloid leukemia . (cellmedicine.com)
  • Figure 1 Survival of acute myeloid leukemia patients (without palliative) according to 1% CD34+CD38- cut-off. (wjgnet.com)
  • 7 In CML and acute myeloid leukemia (AML), we and others have shown that IL-1 is a positive regulator of LSC, and blocking IL-1 signaling inhibits the LSC. (haematologica.org)
  • We identify a mutation (D262N) in the erythroid-affliated transcriptional repressor GFI1B, in an acute myeloid leukemia (AML) patient with antecedent myelodysplastic syndrome (MDS). (lu.se)
  • For births in rural areas only, maternal exposure from offspring birth to cancer diagnosis was positively associated with acute myeloid leukemia ( OR = 2.16, 95% CI 1.09-4.29). (cdc.gov)
  • Moxetumomab pasudotox is an anti-CD22 recombinant immunotoxin indicated for adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least 2 prior systemic therapies, including a purine nucleoside analog. (medscape.com)
  • Randomized Phase II Trial of Rituximab with Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia (NCI-10-C-0025). (cancer.gov)
  • NCI researchers think that combining bendamustine and rituximab may prove effective in treating patients with multiply relapsed or refractory hairy cell leukemia. (cancer.gov)
  • Treating Multiply Relapsed or Refractory Hairy Cell Leukemia was originally published by the National Cancer Institute. (cancer.gov)
  • We conducted a phase 2, single-cohort, 25-center, global study of tisagenlecleucel in pediatric and young adult patients with CD19+ relapsed or refractory B-cell ALL. (nih.gov)
  • FDA medical oncologists discuss the Sept. 13, 2018, approval of moxetumomab pasudotox-tdfk for the treatment of patients with relapsed or refractory hairy cell leukemia. (fda.gov)
  • Today, we'll be discussing the recent approval of moxetumomab pasudotox-tdfk for the treatment of patients with relapsed or refractory hairy cell leukemia. (fda.gov)
  • Moxetumomab pasudotox-tdfk is for adult patients with relapsed or refractory hairy cell leukemia who have had treatment with at least two prior systemic therapies, including at least one purine nucleoside analog. (fda.gov)
  • Signaling Lymphocytic Activation Molecule Family (SLAMF) receptors are a group of nine type I transmembrane receptors that are mainly expressed on a variety of immune cells. (nature.com)
  • When given to mice with aggressive human leukemias, these NK cells reduced the circulating human acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML) cells by 60 to 85 percent. (biologynews.net)
  • C) Peripheral blood cells smear from adult T-lymphocytic leukemia patient 1 (Aus-NR). Tumor cells exhibiting multilobulated nuclei (or flower cells), which are mature activated CD4+ T-lymphocytes. (cdc.gov)
  • Evidence has been obtained for the formation of a new molecular species of the enzyme dihydrofolate reductase in an amethopterin-resistant strain of the mouse lymphocytic leukemia L4946. (karger.com)
  • Vibecotamab is under clinical development by Xencor and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). (pharmaceutical-technology.com)
  • According to GlobalData, Phase I drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. (pharmaceutical-technology.com)
  • Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. (medscape.com)
  • Dr. Kreitman has seen that trend in his own studies involving patients with hairy cell leukemia, including an ongoing clinical trial of rituximab in combination with moxetumomab pasudotox-tdfk (Lumoxiti) (see box). (cancer.gov)
  • Therefore, doctors are interested in finding new treatments or new combinations of existing treatments for patients with hairy cell leukemia who have relapsed or not responded to previous therapies. (cancer.gov)
  • Moreover, rituximab has been used successfully to treat some patients with hairy cell leukemia who have relapsed or not responded to previous chemotherapy. (cancer.gov)
  • Dr. Kreitman is currently directing a randomized clinical trial of rituximab with cladribine in newly diagnosed (untreated) patients and patients who have had only one prior course of cladribine, but no prospective trial has yet evaluated rituximab with pentostatin in patients with hairy cell leukemia. (cancer.gov)
  • In this trial, patients with hairy cell leukemia who have not responded to initial chemotherapy followed by second-line treatment with rituximab, or who have relapsed following two courses of chemotherapy, will be randomly assigned to receive rituximab combined with either pentostatin or bendamustine. (cancer.gov)
  • BACKGROUND AND OBJECTIVES: The management of patients with hairy cell leukemia (HCL) has evolved significantly over the past two decades. (haematologica.org)
  • Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. (medscape.com)
  • Resveratrol-induced apoptosis is enhanced in acute lymphoblastic leukemia cells by modulation of the mitochondrial permeability transition pore. (nature.com)
  • LncRNA NALT interaction with NOTCH1 promoted cell proliferation in pediatric T cell acute lymphoblastic leukemia. (nih.gov)
  • B-cell acute lymphoblastic leukemia is the most common cancer in children, and it's usually successfully treated with chemotherapy. (stanford.edu)
  • The phase-1, dose-escalation study enrolled patients ages 7 to 30 with B cell acute lymphoblastic leukemia who received varying doses of the anti-CD22 CAR T-cell therapy. (stanford.edu)
  • A rare case of T cell acute lymphoblastic leukemia presenting with loss of vision, parotid swelling, hematuria and acute renal failure has been presented in a 40-year-old male. (scirp.org)
  • Acute T cell Lymphoblastic Leukemia should also be kept in differential diagnosis of hematuria, acute renal failure and loss of vision. (scirp.org)
  • N. Gilboa, G. M. Lum and R. E. Urizar, "Early Renal Involvement in Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma in Children," Journal of Urology, Vol. 129, No. 2, 1983, pp. 364-367. (scirp.org)
  • Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, with a male predominance. (sfu.ca)
  • We present a case of a 7-month-old Pakistani male that presented with fever and cough and was subsequently diagnosed with T cell acute lymphoblastic leukemia. (sfu.ca)
  • Obecatagene autoleucel also appears to result in a high rate of minimal residual disease negativity in a population of patients with relapsed/refractory B-cell acute lymphoblastic leukemia. (cancernetwork.com)
  • The global T-cell acute lymphoblastic leukemia market is driven by rise in prevalence of T-cell acute lymphoblastic leukemia. (transparencymarketresearch.com)
  • T-cell acute lymphoblastic leukemia (T-ALL) is a type of acute lymphoblastic leukemia, with features similar to lymphoma. (transparencymarketresearch.com)
  • Rise in prevalence of T-ALL and rapid technological advancements boost the global T-cell acute lymphoblastic leukemia market. (transparencymarketresearch.com)
  • According to the American Society of Clinical Oncology (ASCO), T-cell acute lymphoblastic leukemia accounted for 15% to 20% of all acute lymphoblastic leukemia. (transparencymarketresearch.com)
  • According to a recent study, in 2017, nearly 5,970 cases of acute lymphoblastic leukemia (ALL) were reported in the U.S. About 4 in 10 cases were in adults. (transparencymarketresearch.com)
  • Moreover, increase in health care expenditure and rise in number of clinical trials are expected to fuel the global T-cell acute lymphoblastic leukemia market. (transparencymarketresearch.com)
  • The global T-cell acute lymphoblastic leukemia market has been segmented based on treatment, end-user, and region. (transparencymarketresearch.com)
  • Based on end-user, the global T-cell acute lymphoblastic leukemia market has been categorized into hospitals, clinics, and others. (transparencymarketresearch.com)
  • Moreover, hospitals provide advanced medical treatment to treat T-cell acute lymphoblastic leukemia patients. (transparencymarketresearch.com)
  • In terms of region, the global T-cell acute lymphoblastic leukemia market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. (transparencymarketresearch.com)
  • The market in North America is driven by increase in incidence of T-cell acute lymphoblastic leukemia, new product approvals, strong product pipeline, and rise in health care expenditure. (transparencymarketresearch.com)
  • The T-cell acute lymphoblastic leukemia market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period. (transparencymarketresearch.com)
  • Japan dominated the T-cell acute lymphoblastic leukemia market in the region. (transparencymarketresearch.com)
  • The increasing cases of cancer worldwide and the rising prevalence of lymphoblastic leukemia is likely to emerge as the key driver of the global T-cell acute lymphoblastic leukemia market. (transparencymarketresearch.com)
  • White blood cell acute lymphoblastic leukemia (T-ALL) is a kind of acute lymphoblastic leukemia, with highlights like lymphoma. (transparencymarketresearch.com)
  • Ascend in pervasiveness of T-ALL and fast innovative progressions help the worldwide T-cell acute lymphoblastic leukemia market. (transparencymarketresearch.com)
  • Also, expansion in medical services use and ascend in number of clinical preliminaries are required to fuel the worldwide T-cell acute lymphoblastic leukemia market. (transparencymarketresearch.com)
  • T-cell acute lymphoblastic leukemia (T-ALL) is an uncommon, aggressive malignancy that rarely presents in the skin and is generally not considered as part of the differential diagnosis by dermatologists and dermatopathologists. (karger.com)
  • Acute lymphoblastic leukemia (ALL) is a malignant expansion of lymphoblasts in the bone marrow, blood, and extramedullary tissues [ 1 ]. (karger.com)
  • A study co-led by Dr. Kevin Hay from Vancouver Coastal Health Research Institute (VCHRI) and Dr. Natasha Kekre at The Ottawa Hospital is investigating the use of specialized chimeric antigen receptor T (CAR-T) cells to treat CD19 positive (CD19+) acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). (vchri.ca)
  • Deep sequencing and SNP array analyses of pediatric T-cell acute lymphoblastic leukemia reveal NOTCH1 mutations in minor subclones and a high incidence of uniparental isodisomies affecting CDKN2A. (lu.se)
  • Pediatric T-cell acute lymphoblastic leukemia (T-ALL) is a genetically heterogeneous disease that arises in a multistep fashion through acquisition of several genetic aberrations, subsequently giving rise to a malignant, clonal expansion of T-lymphoblasts. (lu.se)
  • Compounds derived from PS127 significantly upregulated production of reactive oxygen species (ROS) in AML cells and triggered ferroptotic, necroptotic, and/or apoptotic cell death in AML cell lines and refractory/relapsed AML primary samples. (nature.com)
  • There was the abstract we presented, the ZUMA data, showing that prior blinatumomab, even if patients received blinatumomab as their last line of therapy and were refractory, did not impact the likelihood of response to CAR T-cell immunotherapy using what's now called the Tecartus [brexucabtagene, autoleucel] product from Kite. (onclive.com)
  • Hairy cell leukemia is an uncommon cancer of the blood in which the body produces a large number of abnormal B lymphocytes (a type of white blood cell). (cancer.gov)
  • It is called "hairy cell" because the abnormal lymphocytes have hair-like projections when seen under a microscope. (cancer.net)
  • AN: Hairy cell leukemia is a rare and incurable malignancy in which malignant "hairy" B-cell lymphocytes accumulate in bone marrow and interfere with trilineage hematopoiesis. (fda.gov)
  • It affects white blood cells called T lymphocytes. (transparencymarketresearch.com)
  • NHL cancer also affects the immune system's white blood cells, called lymphocytes, and often originates in the lymph nodes, spleen, bone marrow, adrenals, digestive tract or thymus. (vchri.ca)
  • Like multiple myeloma patients, pPCL patients exhibit pathologically high levels of monoclonal plasma cells in their bone marrow plus a malignant plasma cell-secreted circulating monoclonal myeloma protein, either IgG, IgA, a light chain, or none in 28-56%, 4-7%, 23-44%, or 0-12% of cases, respectively. (wikipedia.org)
  • and c) lower rates of bone but higher rates of soft tissue plasma cell tumors termed plasmacytomas. (wikipedia.org)
  • sPCL patients typically are highly symptomatic due to extensive disease with malignant plasma cell infiltrations in, and failures of, not only the bone marrow but also other organs. (wikipedia.org)
  • Fig. 6: Flow cytometry evaluation of viable cell number and apoptosis induction in primary AML samples and healthy bone marrow cells. (nature.com)
  • Leukemia is a form of cancer that affects your blood cells, bone marrow, and other related tissues. (healthline.com)
  • Hairy cell leukemia occurs when abnormal, hairy-looking white blood cells build up in the bone marrow , spleen , and bloodstream. (cancer.gov)
  • Engineered cells persisted at high levels for 6 months in the blood and bone marrow and continued to express the chimeric antigen receptor. (nih.gov)
  • A specific immune response was detected in the bone marrow, accompanied by loss of normal B cells and leukemia cells that express CD19. (nih.gov)
  • Blood cells are made in the bone marrow, the spongy tissue inside the larger bones in the body. (cancer.net)
  • These are found in the bone marrow and develop into cells that fight bacterial infections. (cancer.net)
  • As these cells multiply, they build up in the bone marrow, blood, and spleen. (cancer.net)
  • Each of the participants had either not responded to or relapsed after bone-marrow transplants, and 10 of the 15 patients who had already undergone CD19-targeted treatment no longer expressed any CD19 on the surface of their cancer cells. (stanford.edu)
  • Before undergoing lymphodepletion, 9% blasts were detectable in bone marrow and 0.3% blasts were observed immediately before infusion of 50x106 BE-CAR7 cells. (ajmc.com)
  • For example, if patients had bone marrow (BM) blasts up to 20% during the pre-conditioning stage, treatment was given at 100 x 10 6 CAR T-cell dose and, if any events of cytokine release syndrome (CRS) were below grade 2 and there were no cases of immune effector cell-associated neurotoxicity syndrome (ICANS), obe-cel was administered again at a 310 x 10 6 CAR T-cell dose. (cancernetwork.com)
  • For instance, in November 2021, the Leukemia and Lymphoma Society and Hairy Cell Leukemia Foundation announced a five-year, USD 10 million partnership in support of research on hairy cell leukemia (HCL), a rare hematological malignancy that infiltrates the blood, spleen, bone marrow, and other organs. (mordorintelligence.com)
  • It is an indolent disease characterized by the accumulation of mature monoclonal B cells in the blood and bone marrow, often also involving the spleen, liver, and lymph nodes. (cdlib.org)
  • Dr. Kevin Hay is a clinician scientist at the Terry Fox Laboratory and Leukemia/Bone Marrow Transplant Program of BC and an assistant professor in the Division of Hematology at the University of British Columbia. (vchri.ca)
  • 2 1 There is growing evidence to suggest that primitive CML cells affect the bone marrow (BM) niche, contributing to deregulated cytokine levels. (haematologica.org)
  • This cell infiltrates the patient's reticuloendothelial system and interferes with bone marrow function, resulting in bone marrow failure or pancytopenia. (medscape.com)
  • Accumulation of hairy cells in the bone marrow, liver, and spleen, with very little lymph node involvement, is characteristic of hairy cell leukemia. (medscape.com)
  • This pattern probably results from the expression of the integrin receptor alpha4-beta1 by the hairy cells and the interaction of the receptor with the vascular adhesion molecule-1 (VCAM-1) found in splenic and hepatic endothelia, bone marrow, and splenic stroma. (medscape.com)
  • Leukemia is a malignancy in the blood that develops from the lymphatic system and bone marrow . (bvsalud.org)
  • This fact sheet provides information about the diagnosis and management of mantle cell lymphoma. (lls.org)
  • The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against blood cancer. (lls.org)
  • The LLS mission: Cure leukemia, lymphoma, Hodgkin disease and myeloma, and improve the quality of life of patients and their families. (lls.org)
  • The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. (lls.org)
  • Bendamustine's mechanism of action is different from those of cladribine and pentostatin, and it is known to act synergistically with rituximab in lymphoma cells. (cancer.gov)
  • Support for this program provided by AstraZeneca and The Leukemia & Lymphoma Society. (lls.org)
  • Phase III Study of VCAP-AMP-VECP vs. Biweekly CHOP in Aggressive Adult T-Cell Leukemia-Lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801. (knowcancer.com)
  • Human T-cell leukemia virus type 1 (HTLV-1) is a pathogenic retrovirus that is associated with adult T-cell leukemia/lymphoma (ATL). (kegg.jp)
  • This ulcerated nodule of localized primary cutaneous CD30+ anaplastic large cell lymphoma is relatively nonspecific in appearance. (medscape.com)
  • The clinical presentation of primary PCL (pPCL) indicates a far more aggressive disease than that of a typical multiple myeloma case with its clinical features being a combination of those found in multiple myeloma and acute leukemia. (wikipedia.org)
  • In a pilot study published in Clinical Cancer Research , the Johns Hopkins investigators used a vaccine made from CML cells irradiated to halt their cancerous potential and genetically altered to produce an immune system stimulator called GM-CSF. (sciencedaily.com)
  • Crystal Mackall and her collaborators found in a small clinical trial that a new type of cell therapy helped children and young adults whose B-cell leukemia had returned. (stanford.edu)
  • U. , D. Santhosh, S. Kumar, R. Singh and J. Prakash, "Adult Acute T Cell Leukemia Presenting as Acute Renal Failure, Parotid Swelling and Loss of Vision," International Journal of Clinical Medicine , Vol. 5 No. 1, 2014, pp. 32-35. (scirp.org)
  • Additionally, the increase in funding for companies and rising focus on adopting various business strategies such as partnerships, and conducting clinical trials related to hairy cell leukemia is expected to boost the studied market. (mordorintelligence.com)
  • This case highlights the importance of considering leukemia cutis in patients with underlying CLL presenting with unusual clinical features. (cdlib.org)
  • This first-of-its-kind clinical trial in Canada involves manufacturing and administering a CLIC-1901 cell therapy, which could add to current treatments available to the thousands of Canadians diagnosed with ALL and NHL each year. (vchri.ca)
  • This is a completely Canadian-designed and led product: from the genetic engineering of the cells at BC Cancer using vector manufactured at The Ottawa Hospital all the way to the clinical administration at Vancouver General Hospital, with monitoring of trial patients supported by the VCHRI Hematology Research Program," says Hay. (vchri.ca)
  • Overexpression of SLAMF1 or SLAMF7 in IGHV mutated CLL cell models resulted in reduced proliferation and impaired responses to BCR ligation, whereas the knockout of both receptors showed opposing effects and increased sensitivity toward inhibition of components of the BCR pathway. (nature.com)
  • The obtained data led us to hypothesize on the mechanisms of regulation of signalling propensity of two pathways that are responsible for proliferation and survival of CLL cells, namely B Cell Receptor (BCR) signalling and signals from T-cells mediated by CD40/IL4. (europa.eu)
  • Its roles include regulation of proliferation, promotion of immune system and activation of apoptosis in B cells. (intechopen.com)
  • In these cells, IL-21 does not promote proliferation but enhances apoptosis and chemotaxis. (intechopen.com)
  • Tax is a transcriptional co-factor that interfere several signaling pathways related to anti-apoptosis or cell proliferation. (kegg.jp)
  • Hairy cell leukemia is recognized as a clonal B-cell malignancy, as identified by immunoglobulin gene rearrangements that result in a phenotype B-cell expression of surface antigens. (medscape.com)
  • Patrick Zweidler-McKay, M.D., Ph.D., assistant professor of pediatrics from the Children's Cancer Hospital at M. D. Anderson, has shown an effective method for expanding the number of NK cells from a single cord blood unit while retaining the cells' anti-leukemia effects, as presented at the American Society of Pediatric Hematology/Oncology annual conference on May 16. (biologynews.net)
  • If hairy cell leukemia comes back after or doesn't respond to initial treatment with chemotherapy, patients have several treatment options. (cancer.gov)
  • The Italian research team is planning a follow-up trial that will compare vemurafenib plus rituximab with chemotherapy for people who are newly diagnosed with hairy cell leukemia, said lead investigator Enrico Tiacci, M.D., of the University and Hospital of Perugia, Italy. (cancer.gov)
  • Hairy cell leukemia is usually treated with a chemotherapy drug called cladribine when signs or symptoms of the disease develop, such as low blood cell counts, recurrent infections, or a swollen spleen. (cancer.gov)
  • In order to evaluate the compound's efficacy against leukemia, a team of researchers at the St George's, University of London studied cancer cells in a laboratory and tested various combinations of cannabinoids and chemotherapy drugs such as cytarabine and vincristine. (naturalnews.com)
  • With Murad's condition not responding to chemotherapy, our hematologists and scientists worked closely with Murad's treating physicians at Sheikh Khalifa Medical City (SKMC) for a smooth transfer to ADSCC to receive CAR-T cell therapy, the only effective treatment for his condition. (zawya.com)
  • Once the process is complete, the NK cells can be transplanted to patients without prior chemotherapy. (biologynews.net)
  • The Hairy Cell Leukemia Market is Segmented by Therapy (Chemotherapy and Targeted Therapy) and by Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). (mordorintelligence.com)
  • The chemotherapy segment is expected to witness significant growth in the hairy cell leukemia market over the forecast period. (mordorintelligence.com)
  • The key factor contributing to the growth of the chemotherapy segment is the rising incidence of leukemia cases. (mordorintelligence.com)
  • Chemotherapy drugs, specifically purine analogs such as cladribine and pentostatin, are considered an initial treatment option for most individuals with hairy cell leukemia. (mordorintelligence.com)
  • We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the B-cell antigen CD19, coupled with CD137 (a costimulatory receptor in T cells [4-1BB]) and CD3-zeta (a signal-transduction component of the T-cell antigen receptor) signaling domains. (nih.gov)
  • Apart from the tumor lysis syndrome, the only other grade 3/4 toxic effect related to chimeric antigen receptor T cells was lymphopenia. (nih.gov)
  • The therapy is similar to but distinct from CD19-targeted chimeric antigen receptor T-cell therapy, or CAR T-cell therapy, in which a patient's T cells are genetically modified to target a molecule called CD19 on the surface of the cancer cells. (stanford.edu)
  • T-cells are taken from patients' blood and given a benign form of lentivirus-a virus designed so that it cannot replicate-that carries the chimeric antigen receptor gene into the T-cell. (vchri.ca)
  • Patient 2 was a 13-year-old boy with a diagnosis of cortical T-cell ALL 3 years prior to study enrollment, who had relapsed while receiving maintenance treatment. (ajmc.com)
  • Certain factors that are expected to propel market growth are the growing burden of leukemia cases, the increasing diagnosis rate, and the growing geriatric population. (mordorintelligence.com)
  • Immunostaining for terminal deoxynucleotidyl transferase (TdT) was positive in tumor cells, supporting the diagnosis of cutaneous involvement by T-ALL. (karger.com)
  • Leukemic cell infiltration of the skin (i.e., leukemia cutis) typically occurs after the diagnosis of leukemia and may precede the appearance of leukemic blasts in the peripheral blood [ 2 ]. (karger.com)
  • Recently, new DNA scanning techniques using whole-exome sequencing identified 5 missense somatic clonal mutations, including a heterozygous mutation in BRAF that results in the BRAF V600E variant protein, which is oncogenic for other tumors as well, was identified in all hairy cell leukemia patients and may be responsible for the pathogenesis, diagnosis, and targeted therapy of hairy cell leukemia. (medscape.com)
  • Results: For births 1968-2016, paternal exposure from offspring birth to cancer diagnosis was associated with central nervous system tumors (adjusted odds ratio [OR] = 1.30, 95% confidence interval [CI] 1.04-1.63) and germ cell tumors (OR = 1.82, 95% CI 1.05-3.27), while maternal pregnancy exposure was associated with astrocytoma ( OR = 1.89, 95% CI 1.00-3.57). (cdc.gov)
  • 2012. According to international standards, cytogenetic and molecular examination determined that this form of leukemia was "poor risk" at the time of diagnosis. (cdc.gov)
  • The main risk still remains the "graft-versus-host reaction", in which donor cells attack the patient's own cells, which are foreign to them. (disabled-world.com)
  • He also noted that he will not recommend smoking marijuana to treat leukemia as it remains uncertain how various chemicals interacts inside a patient's body. (naturalnews.com)
  • The new therapy genetically modifies a patient's T cells to target a different molecule called CD22. (stanford.edu)
  • CAR T-cell therapy relies on a patient's own T cells - a type of immune cell that can be a powerful killing machine. (stanford.edu)
  • However, given the patient's history of CLL, a panel of immunohistochemical stains was performed on both biopsies revealing aggregates and individual CD20+ B cells in both perivascular and periadnexal locations. (cdlib.org)
  • HTLV-1 is the etiological agent of adult T-cell leukemia (ATL), a poorly treatable and prevalently fatal disease. (nih.gov)
  • Trowbridge hypothesized that analyzing open chromatin in bulk tumor cells could provide a possible improved method to identify cancer cell of origin because of the cell-type specificity of chromatin structure. (news-medical.net)
  • ALCL was recognized in 1985, when tumor cells consistently demonstrated labeling by the monoclonal antibody Ki-1, a marker later shown to recognize the CD30 antigen. (medscape.com)
  • More than 15 years ago, cholesterol decrement was first shown to inhibit tumor cell growth, metastasis of tumor cells, and induction of apoptosis (7). (cdc.gov)
  • Plasma cell leukemia (PCL) is a plasma cell dyscrasia, i.e. a disease involving the malignant degeneration of a subtype of white blood cells called plasma cells. (wikipedia.org)
  • We aim to reveal how the malignant B cells change the propensity of their signalling pathways in response to the different microenvironments such as peripheral blood vs lymph node to obtain the proliferative signals. (europa.eu)
  • PC-ALCL is one of the primary cutaneous CD30 + T-cell lymphoproliferative disorders, a wide spectrum of disease, with lymphomatoid papulosis (LyP) at the benign end of the spectrum and PC-ALCL at the malignant end. (medscape.com)
  • Cell Death Dis, 2022 Nov 16. (nih.gov)
  • For example, according to data published by the Mayo Clinic in 2022, hairy cell leukemia typically affects people in their 50s or 60s. (mordorintelligence.com)
  • Since the SLAMF low signature was strongly associated with an unmutated CLL immunoglobulin heavy chain (IGHV) status in large datasets, we investigated the impact of SLAMF1 and SLAMF7 on the B cell receptor (BCR) signaling axis. (nature.com)
  • The investigators then used base editing to inactivate 3 genes encoding CD52 and CD7 receptors and the b chain of the ab T-cell receptor to evade lymphodepleting serotherapy, CAR7 T-cell fratricide, and graft-versus-host disease, respectively. (ajmc.com)
  • A critical component in CLL pathogenesis is the activation of the B-cell receptor signalling taking place in lymph nodes, and in the context of other microenvironmental interactions (such as CLL-T cell interaction). (europa.eu)
  • This study is a "proof of principle" that adding rituximab to another therapy for hairy cell leukemia often makes the treatment more effective, said Robert Kreitman, M.D., of NCI's Center for Cancer Research , who was not involved in the study. (cancer.gov)
  • Although the hairy cells that remain after cladribine or pentostatin treatment are essentially always CD20 positive, only a minority of patients respond to rituximab therapy alone. (cancer.gov)
  • These remaining cells are a source of relapse, according to the investigators, especially if Gleevec therapy is stopped. (sciencedaily.com)
  • Instead of targeting a molecule called CD19 on the surface of the cancer cells, the new therapy targets a molecule called CD22. (stanford.edu)
  • The new approach is helpful because the cancer cells of some patients who undergo CD19-directed CAR T-cell therapy stop expressing the CD19 molecule on the cell surface. (stanford.edu)
  • Researchers hope that targeting CD19 and CD22 simultaneously may result in a powerful therapy - one that cancer cells are unable to evade. (stanford.edu)
  • At that point, CAR-T cell therapy was the only treatment option available for him. (zawya.com)
  • CAR-T therapy is a remarkable advancement for fighting diseases using the body's immune system, and there was a pressing need to make CAR T cells available in UAE. (zawya.com)
  • A doctoral scholarship from the Deutsche José Carreras Leukämie-Stiftung for Keshia Aerchlimann (Fraunhofer Institute for Cell Therapy and Immunology) supports the development of an organ-on-a-chip model for the cultivation and investigation of leukemia cells. (fraunhofer.de)
  • The Deutsche José Carreras Leukämie-Stiftung is supporting Keshia Aerchlimann's research work at the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig with a doctoral scholarship. (fraunhofer.de)
  • Researchers from The University of Texas M. D. Anderson Cancer Center have found a therapy that effectively kills human leukemia cells in mice using natural killer (NK) cells from umbilical cord blood. (biologynews.net)
  • The use of base editing to generate universal, off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with potential implications for the future of gene therapy. (ajmc.com)
  • Obe-cel is a CD19-directed CAR T-cell therapy, designed to mitigate safety concerns and improve persistence, she explained. (cancernetwork.com)
  • We've seen in now multiple studies, the more heavily pretreated the patient, the less likely even CAR T-cell therapy is going to work, and that may be a reflection of T-cell fitness or other factors that we haven't assessed. (onclive.com)
  • We have to deal with the reality that CAR T-cell therapy is not yet approved in the first-relapse setting. (onclive.com)
  • Researchers are developing systems that could put Canada on the map for adoptive cell therapy for leukemia and other conditions. (vchri.ca)
  • Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. (medscape.com)
  • Leukemia treatment is vulnerable to cellular heterogeneity as rare LSCs often evade therapy and cause relapse. (lu.se)
  • This section focuses on prolymphocytic leukemia (PLL) and hairy cell leukemia (HCL). (cancer.net)
  • There is classification sysytem for B-cell prolymphocytic leukemia . (wikidoc.org)
  • No criteria for the classification of B-cell prolymphocytic leukemia has emerged. (wikidoc.org)
  • In a very small percentage of these cases, the progressive development of further genetic abnormalities serially create a clone(s) of plasma cells that cause the more serious but still premalignant disorder of smoldering multiple myeloma, overt myeloma cancer, and ultimately sPCL. (wikipedia.org)
  • Fig. 2: Mitochondria-related mechanistic effects of PS hit compounds on cancer and normal blood cells. (nature.com)
  • Fig. 5: PS compounds induced synergistic cytotoxicity when combined with other anti-cancer drugs in AML cell lines and primary AML samples. (nature.com)
  • Inflammation and metabolism in cancer cell-mitochondria key player. (nature.com)
  • Hairy cell leukemia-variant is an extremely rare and unique type of leukemia (cancer) that was once grouped with another type but is now considered a separate condition. (healthline.com)
  • Although this rare cancer usually grows slowly, the leukemia cells eventually crowd out healthy blood cells. (cancer.gov)
  • They discovered that almost all people with hairy cell leukemia have a mutant form of the BRAF protein in their cancer cells. (cancer.gov)
  • The mutant protein sends out signals that speed the growth of the cancer cells, they found. (cancer.gov)
  • Similarly, treating hairy cell leukemia with rituximab-a drug that binds to a protein called CD20 on white blood cells-doesn't typically eliminate all of the cancer. (cancer.gov)
  • Gleevec, one of the first targeted cancer therapies with wide success in CML patients, destroys most leukemic cells in the body, but in most patients, some cancerous cells remain and are measurable with sensitive molecular tests. (sciencedaily.com)
  • The study vaccine was given to 19 CML patients with measurable cancer cells, despite taking Gleevec for at least one year. (sciencedaily.com)
  • After a median of 72 months of follow-up, the number of remaining cancer cells declined in 13 patients, 12 of whom reached their lowest levels of residual cancer cells. (sciencedaily.com)
  • We want to get rid of every last cancer cell in the body, and using cancer vaccines may be a good way to mop up residual disease," says Hyam Levitsky, M.D., professor of oncology, medicine and urology at the Johns Hopkins Kimmel Cancer Center. (sciencedaily.com)
  • Often patients have low blood cell counts, fluid retention, significant nausea and other gastrointestinal problems," says B. Douglas Smith, M.D., associate professor of oncology at the Johns Hopkins Kimmel Cancer Center. (sciencedaily.com)
  • Every cancer starts with a single cell, and Jackson Laboratory (JAX) researchers have found a precise and reliable way -- whole-genome profiling of open chromatin -- to identify the kind of cell that leads to a given case of leukemia, a valuable key to cancer prognosis and outcome. (news-medical.net)
  • Knowing the cell of origin of cancer cells can provide insight into tumor subtypes and possibly diagnostic and therapeutic benefit,' says JAX Assistant Professor Jennifer Trowbridge, Ph.D., the lead author of the study published on July 11 in Nature Communications . (news-medical.net)
  • This is the first page of Cancer.Net's Guide to B-Cell Leukemia. (cancer.net)
  • Leukemia is a cancer of the blood cells. (cancer.net)
  • A recent study published in International Journal of Oncology revealed that cannabinoids, the active chemical in cannabis, can destroy leukemia cells either alone or in combination with other cancer treatments. (naturalnews.com)
  • The scientific community has long-established that cannabinoids may show potential in cancer treatment, with certain varieties known to promote cell death, curb cell growth, and inhibit tumor-inducing blood vessel development. (naturalnews.com)
  • The researcher found that the compounds spurred significant declines in cancer cell viability and simultaneously inhibited all phases of the cell cycle. (naturalnews.com)
  • Researchers genetically modify the T cells to recognize specific molecules on the cancer cells' surfaces and kill the cells. (stanford.edu)
  • But patients whose cancer cells don't express CD19, or which tamp down their expression to evade the treatment, either don't respond or can relapse. (stanford.edu)
  • Mackall and her colleagues wondered if there was another molecule on the cancer cells that could also be a good target. (stanford.edu)
  • Engineered CAR-T cells therapies are recognized as a breakthrough in blood cancer treatment. (zawya.com)
  • Physicians withdrew the cells from the patient and genetically modified his immune cells in the laboratory to fight the cancer cells after intravenously injecting them into the patient. (zawya.com)
  • Our scientists pursue every aspect of cancer research-from exploring the biology of genes and cells, to developing immune-based treatments, uncovering the causes of metastasis, and more. (mskcc.org)
  • The first from Nirali Shah, MD, MHSc, from the NCI [National Cancer Institute], their consortium of investigators suggested that maybe there is an impact on both CD19 antigen density and the likelihood of response to subsequent CAR T-cell immunotherapy. (onclive.com)
  • The CLIC-1901 army of CAR-T cells is designed to ramp up when more cancer cells are present, and scale down once the cancer has been eliminated. (vchri.ca)
  • A few CAR-T cells then remain in the body to help prevent the cancer from coming back. (vchri.ca)
  • It works by killing cancer cells. (medlineplus.gov)
  • For patient education information, see the Cancer Center , as well as Leukemia . (medscape.com)
  • Available at http://www.cancer.gov/cancertopics/pdq/treatment/hairy-cell-leukemia/HealthProfessional. (medscape.com)
  • New research in clustered regularly interspaced short palindromic repeats (CRISPR) technology suggests that base-edited T cells could be useful in patients with relapsed leukemia and could help anticipate the risks of immunotherapy -related complications. (ajmc.com)
  • We've seen durable remissions with CAR T-cell immunotherapy. (onclive.com)
  • One rare form of leukemia is hairy cell leukemia (HCL) , named for the hair-like filaments found on affected white blood cells. (healthline.com)
  • CLL is the most frequent form of leukemia in western countries. (disabled-world.com)
  • HCL is a slow-growing form of leukemia. (cancer.net)
  • In summary, we identify myostatin propeptide as a novel positive regulator of primitive CML cells and corresponding normal hematopoietic cells. (haematologica.org)
  • GFI1B-D262N promoted myelomonocytic versus erythroid output from primary human hematopoietic precursors and enhanced cell survival of both normal and MDS derived precursors. (lu.se)
  • Mechanistically, all hit compounds reduced ATP and selectively impaired both basal and ATP-linked oxygen consumption in leukemic cells. (nature.com)
  • Pilot in vivo efficacy studies indicate anti-leukemic efficacy in a MOLM14/GFP/LUC xenograft model, including extended survival in mice injected with leukemic cells pre-treated with PS127B or PS127E and in mice treated with PS127E at a dose of 5 mg/kg. (nature.com)
  • Fig. 3: Mitochondrial respiration in leukemic cells is selectively inhibited by PS leads. (nature.com)
  • Cytokines are essential for the function and maintenance of cells, and altered cytokine levels influence not only leukemic cells, but also the normal HSC within the BM. (haematologica.org)
  • CD3 (A) and CD4 (B) cells immunostained with diaminobenzidine and horseradish peroxidase in lymph node biopsy sample from patient 2 (Aus-GM). (cdc.gov)
  • This includes analysis of CLL samples at various times during the disease course, during microenvironment-targeting therapies, and comparison of CLL cells in lymph nodes and peripheral blood. (europa.eu)
  • Structure-activity relationship studies identified six analogs from two original scaffolds that had over an order of magnitude difference between LD50 in AML and healthy peripheral blood mononuclear cells. (nature.com)
  • The pharmacological NFkappaB inhibitors BAY117082 and MG132 induce cell arrest and apoptosis in leukemia cells through ROS-mitochondria pathway activation. (nature.com)
  • AVM induced the release of cleaved PARP and cleaved caspase‑3 caused apoptosis and inhibited the viability of these cells. (spandidos-publications.com)
  • While ALL mostly affects children, Hay's study is investigating a treatment that would be a first for adults with a class of ALL that involves B-cells-a type of white blood cell that forms part of the body's infection-fighting immune response. (vchri.ca)
  • A biological agent called rituximab binds to and kills cells that express an antigen called CD20 (CD20-positive cells). (cancer.gov)
  • This changes the genetic code of T-cells, transforming them into CAR-T cells that can target the CD19 antigen. (vchri.ca)
  • It is an extended bi-specific monoclonal antibody which contains both tumor antigen binding domain CD123 and cytotoxic T-cell binding domain (CD3 binding domain). (pharmaceutical-technology.com)
  • Anaplastic large cell lymphomas (ALCLs) are distinguished from other lymphomas by their anaplastic cytology and constant membrane expression of the CD30 antigen (an activation marker for B or T cells). (medscape.com)
  • Fifteen of the 21 patients in the phase-1 study had previously either relapsed or failed to respond to anti-CD19 CAR T-cell treatment, which is currently used only when all other therapies have failed. (stanford.edu)
  • Antibody therapies that target the CD19 protein found on the surface of B-cells are often used to treat CD19+ NHL, of which the novel CLIC-1901 treatment would be one. (vchri.ca)
  • We have already seen that cell therapies targeting CD19 CAR-T cells have dramatically changed the field of cell therapies both in Canada and around the world," says Hay. (vchri.ca)
  • Fig. 4: PS molecules induce different cell death pathways. (nature.com)
  • In this chapter, we will focus on IL-21's biological effects and signaling pathways as well as discuss the potential implications and applications of IL-21 in leukemia cells. (intechopen.com)
  • The Tax protein has pleiotropic effects on host-cell gene expression and activates several pathways such as the cyclic AMP responsive binding protein (CREB), the nuclear factor kappa-B (NF-κB), the cyclin-dependant kinases (CDKs), and the Akt pathways. (nih.gov)
  • The Tax protein has pleiotropic effects on host-cell gene expression and activates several pathways such as the cyclic AMP responsive binding protein (CREB), the nuclear factor kappa-B, the cyclin-dependant kinases (CDKs), and the Akt pathways. (nih.gov)
  • 1 The BCR-ABL1 fusion protein is a constitutively active tyrosine kinase and triggers a cascade of aberrant downstream signaling pathways leading to clonal outgrowth of CML cells and subsequent disease manifestation. (haematologica.org)
  • Although various treatment options have been used for different types of leukemia , understanding the molecular pathways involved in the development and progression of leukemia is necessary. (bvsalud.org)
  • It is the terminal stage and most aggressive form of these dyscrasias, constituting 2% to 4% of all cases of plasma cell malignancies. (wikipedia.org)
  • This is of major relevance for CLL, but also transferable to the biology of some other B cell malignancies and/or normal B cells. (europa.eu)
  • These genetic abnormalities effect the Wnt signaling pathway, regulation of the cell cycle, RNA metabolism, protein folding, and cadherin-related cell adherence to extracellular matrix. (wikipedia.org)
  • NK cells operate differently from T cells, leaving normal cells alone while targeting and killing the cancerous cells. (biologynews.net)
  • I like to compare it to 'whack-a-mole', in that the remaining CAR-T cells can find and whack or destroy any cancerous cells that try to come back. (vchri.ca)
  • Let's take a look at the basics of HCL-V and how it's different from other types of leukemia. (healthline.com)
  • These are other, less common types of leukemia, but they are generally subcategories of 1 of the 4 main categories. (cancer.net)
  • What is the survival rate of hairy cell leukemia-variant? (healthline.com)
  • CLL cells are characterized by their universal dependency on pro-survival and pro-proliferative signals from immune niches. (europa.eu)
  • It is crucial to control the transplanted donor immune cells so that the effect is strong enough to eliminate the leukemia cells but not strong enough to lead to complications in other tissues and organs. (disabled-world.com)
  • The procedure involved manufacturing the cellular product (CAR-T), which relies on the use of immune cells from the patient, at ADSCC's Good Manufacturing Practices (GMP) laboratories - one of very few laboratories in the Middle East. (zawya.com)
  • It often prevents your white blood cells from working correctly. (healthline.com)
  • Healthy white blood cells come in many types that all work together to help fight infections and disease. (healthline.com)
  • The lab will look at what types of cells are in your blood, their shapes, and their relative quantities. (healthline.com)
  • Hairy cell leukemia is so named because the cancerous blood cells (purple) appear "hairy" when viewed with a microscope. (cancer.gov)
  • As a result, patients suffer from infections, low numbers of healthy blood cells, and swelling in the spleen. (cancer.gov)
  • In about half of these patients, no remaining CLL cells were detected in the blood in the long term, which was highly predictive for the lack of recurrence for the follow-up period (up to eight years, on average about four years). (disabled-world.com)
  • For this, regular measurement of the CLL cells in blood is a new, extremely helpful instrument," says Professor Dreger. (disabled-world.com)
  • Leukemia begins when healthy blood cells change and grow out of control. (cancer.net)
  • Previous efforts to expand cord blood have resulted in ineffective NK cells. (biologynews.net)
  • Cord blood is a promising source of natural killer cells because the NK cells have enhanced sensitivity to stimulation, decreased potential to cause graft-versus-host disease and are available from cord banks throughout the country and world," says Zweidler-McKay. (biologynews.net)
  • Zweidler-McKay's study involves selecting out NK cells from cord blood. (biologynews.net)
  • As the cord blood is expanded to multiply in number, the NK cells are given a cytokine, interleukin-2, and a target cell, K562, which keep the NK cells active throughout the three week expansion. (biologynews.net)
  • These results support the evaluation of cord blood-derived NK cells as a potential immuno-therapeutic approach in acute leukemias. (biologynews.net)
  • MSK investigators have used a lab tool originally developed to study fly nerve cells to study RNA-binding proteins in blood cells from mammals. (mskcc.org)
  • Ongoing neutropenia and lymphopenia were challenges throughout the investigational period, and BE-CAR7 T cells were detected at serial time points in blood, marrow, and pleural fluid. (ajmc.com)
  • ALL-affected blood cells can multiply rapidly and enter the bloodstream where they can travel to and infect organs. (vchri.ca)
  • This image demonstrates a lymphocytosis and an absence of any other type of blood cell (pancytopenia). (medscape.com)
  • toxicity pro le, can be used in cases to increase blood cell predilection, with a ratio of 5:1. (bvsalud.org)
  • blood containing classic hairy cells - medium size center. (bvsalud.org)
  • These abnormal cells appear "hairy" when viewed under a microscope and give the disease its name. (cancer.gov)
  • But this entails serious consequences: the appearance of abnormal cells, which accumulate errors and trigger leukaemia initiation. (gulbenkian.pt)
  • Interleukin-21 (IL-21) is produced by activated T cells and it plays many diverse roles by regulating the functions of normal and abnormal cells. (intechopen.com)
  • Examination of plasma cell immunophenotype by measuring certain of their cell surface antigens, particularly Cluster of differentiation. (wikipedia.org)
  • The treated cells also carry molecules, called antigens, specific to CML cells, which prime the immune system to recognize and kill circulating CML cells. (sciencedaily.com)
  • Sixty percent of cases express 1 or more T-cell antigens (CD3 + , CD43, or CD45RO). (medscape.com)
  • The exact causes of CLLs aren't known, but experts believe that genetic changes - called mutations - can cause your B cells to multiply too often. (healthline.com)